Structure-function studies of fibroblast growth factors (FGFS) by Zhu, Xiaotian




Partial Fulfillment of the Requirements 
for the Degree of 
Doctor of Philosophy 
California Institute of Technology 
Pasadena, California 
1993 
(submitted February 16, 1993) 
Dedicated to my family 
ii 
Acknowledgments 
I would like to thank my advisor Professor Doug Rees for his support, 
encouragement and invaluable guidance during my stay in graduate school. In 
addition to showing me the beauty of macromolecular crystallography, Doug has 
been fully involved in my research project and has always been of great help 
whenever I encountered difficulties. Also, my research project has been carried along 
with his encouragement and understanding. By working closely with him in the past 
few years, I have been constantly inspired by his enthusiastic attitude towards science 
as well as his correct but simple ways of attacking scientific problems. 
I am deeply indebted to Barbara Hsu who has been giving me enormous help 
since I joined this research group. With her breadth of scientific knowledge, she has 
helped me in each stage of my research. I also cherish the friendship that has 
developed between us in all these years. 
I also owe many thanks to Art Chirino. Art not only has taught me the basic 
crystallographic theories and experimental manipulations when I first came to the 
field of crystallography, but has helped me all the way along. His patience and 
contributions are greatly appreciated. 
Thanks also go to Salem Faham for his participation and contribution to this 
project. I would also like to thank Hiromi Komiya, Millie Georgiadis, Debbie Woo, 
Michael Stowell, Mike Day and Larry Henleig as well as other members of Rees' 
group for their help. 
Special thanks go to Kam Zhang for his help with the CCP4 programs and many 
stimulating discussions. 
iii 
I am grateful to Drs. T. Arakawa and G. M. Fox of Amgen who have provided us 
with large amounts of protein samples for the structural studies of FGFs. 
I would like to thank Professors Sunney Chan and Pamela Bjorkman for their help 
and advice. 
Finally, thanks to my parents and my sister for their love and encouragement. I 
wish to thank my wife, Hongying Xie for her companionship, understanding and 
great support during these years. Many discussions with her about my research have 
been truly stimulating. 
IV 
Abstract 
The fibroblast growth factor (FGF) family exhibits mitogenic, chemotactic and 
angiogenic activity in a variety of cell types. The first three-dimensional structures of 
two members of the FGF family, bovine acidic FGF (aFGF) and human basic FGF 
(bFGF), have been crystallographically determined by multiple isomorphous 
replacement (MIR), and refined to 2.7 A and 1.9 A respectively. The structures of 
both aFGF and bFGF consist of twelve antiparallel J3 strands which are arranged in a 
folding pattern with approximate three-fold internal symmetry. A striking feature of 
the FGF structures is the overall similarity to the structures of soybean trypsin 
inhibitor and interleukins-la and 1J3, in spite of the low sequence homology between 
these proteins. 
FGF stimulates cellular proliferation and differentiation through the interactions 
with both the cell surface FGF receptor and heparin. In the FGF structures, the two 
putative receptor binding sites are located on different sides of FGF. Also, a region 
rich in positively charged amino acids that is likely involved in heparin binding has 
been found in the FGF structures. It is further shown that the putative heparin and 
receptor binding regions occupy distinct locations on the protein surface. 
Because heparin is required for FGF binding to its receptor, the interactions 
between FGF and sucrose octasulfate, a heparin analog, have been studied. The 
crystal structure of the complex between aFGF and sucrose octasulfate has been 
determined to 2. 7 A resolution by a combination of MIR and molecular replacement 
methods. Sucrose octasulfate binds to the aFGF positive patch mentioned above as a 
potential heparin binding site. Based on the structure of aFGF and sucrose octasulfate 
v 
complex, a possible FGF receptor binding mechanism in the presence of heparin is 
proposed. 
Other crystallographic studies of FGF include the structural determination of the 
two FGF mutants; the complex of aFGF and 1,3,6-naphthalene trisulfonate, a close 
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Chapter 1 
General Introduction to Fibroblast Growth Factors (FGFs) 
1 
Growth is a fundamental process in all living organisms. It is not only associated 
with the early stages of development, but remains a general feature in many tissues. It 
has long been known that cell proliferation and differentiation are strictly modulated 
by hormones. Hormones can be amino acid derivatives, or cholesterol based steroid, 
or polypeptide growth factors (1). The knowledge about polypeptide growth factors is 
relatively scarce compared to that of other hormones due to the difficulty of protein 
purification. But with the rapid development of protein purification and molecular 
biology techniques, more and more polypeptide growth factors have been recognized, 
isolated and cloned and their biological functions have been further investigated (2). 
The knowledge of how these polypeptide growth factors are triggered and interact 
with their target cells is critical for understanding the origin, development and 
maintenance of life. 
Fibroblast growth factors (FGFs), belong to the polypeptide growth factor family 
that can stimulate and regulate cellular growth and development. Although it was 
originally purified from fibroblast cells (3, 4), FGF has been revealed to be mitogenic, 
chemotactic and angiogenic to a wide spectrum of cells (5, 6, 7). In addition, FGF is 
also an important neurotropic effector which can influence the proliferation and 
differentiation of neuroectoderm derived cells (7). The FGF family contains at least 
seven homologous proteins. This includes the two original members: acidic and basic 
FGF (8, 9), the four oncogene products: int-2/KS3/K-fgf, hst, FGF5, FGF6 (10-16) 
and keratinocyte growth factor (17). As a consequence of their strong affinity for 
heparin, FGF is also often referred to as heparin-binding growth factor (HBGF). The 
FGF family members have quite high sequence homology and similar biological 
activities (Figure 1.1). For instance, the two original members of the FGF family, 
aFGF and bFGF, share 55% sequence identity over the 140 amino acid length and 
have been shown to display similar activities to most cell types (18). On the other 
hand, functional differences between these growth factors definitely exist. For 
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example, while normal members of the FGF family lack the leader signal peptides in 
their sequences, all the proto-oncogene FGF products possess a hydrophobic peptide 
sequence at their amino terminus. Another example supporting the unique roles of 
each FGF family member is that KGF has been demonstrated to be much more potent 
than acidic and basic FGF in stimulating the growth of epithelial cells (19) and 
further, bFGF appears to lack binding affinity for KGF receptors (20). 
The mitogenic response initiated by FGF is, in common with most peptide growth 
factors, mediated through cellular FGF receptors (7). Kinetic studies indicate there are 
two types of receptors on the cell surface which participate in FGF binding. One is a 
high affinity receptor (Kd = to-ll M) (21-23) and the other one is a low affinity 
receptor (Kd = t0-9 M) (24, 25). Both aFGF and bFGF have been cross-linked to one 
high affinity FGF receptor which has an approximate molecular weight of 130 kD 
(26). At present, at least four high affinity FGF receptors have been identified and 
cloned, each encoding a receptor that responds to one or more of the FGFs (27). The 
first FGF receptor, FGFRl, was purified from chicken embryos and the 
corresponding gene was identified as the chicken cekl gene and humanflg gene. The 
derived amino acid sequence from the isolated gene reveals that the FGF receptor 
belongs to the class of membrane tyrosine kinase (28). It consists of two or three 
extracellular immunoglobulin-like domains, one transmembrane helix and one 
intracellular tyrosine kinase domain. FGFRl has been shown to have equal binding 
affinity for aFGF and bFGF but with about 10 times lower affinity for KGF (29, 30). 
The second member of the FGF receptor family, FGFR2, is homologous to FGFRl. 
Being encoded by the related genes bek, ck3, K-sam and TK14 (29, 31-33), FGFR2 
binds aFGF and bFGF equally well but has little binding affinity for FGF-5 (29). 
With the structural similarity in the primary sequence with FGFRl and FGFR2, 
FGFR3 responds to both aFGF and bFGF (34). Recently FGFR4 has been identified 
(35) and it exhibits the highest affinity for aFGF followed by K-fgf and bFGF (36). In 
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addition, the FGF receptor is complicated by the fact that each FGF receptor gene 
may give rise to three or more different forms as a result of alternative mRNA 
splicing (37). Therefore, FGF receptors with either two or three extracellular 
immunoglobulin-like domains and different lengths of the intracellular tyrosine 
kinase domains have been observed (37) 
After binding of FGF to the tyrosine kinase receptor, the high affinity receptors 
are dimerized and subsequently the intracellular tyrosine kinase activity is switched 
on via an autophosphorylation mechanism (38, 39). Although the signal from FGF is 
known to be ultimately transduced into the nucleus to induce DNA synthesis, the 
detailed signal pathway remains unclear. A cascade of phosphorylation could be 
involved because it is reported that incubation of FGF with 3T3 cells results in 
phosphorylation of a series of proteins (40). Recently, phospholipase C-y (PLC-y) has 
been suggested to be a major substrate of FGFRl (41). Furthermore, calcium 
concentration also appears to be connected with the level of expression of FGF 
receptors (42). 
In addition to the high affinity receptors, low affinity FGF binding sites have been 
characterized and shown to be heparin or heparin-like proteoglycans which are 
located on the cell surface or in the extracellular matrix (43-46). Binding of FGF to 
heparin not only provides a convenient way for the protein purification but also 
stabilizes and potentiates FGF activities (47). Recent studies have further 
demonstrated that binding of FGF to the receptor absolutely requires the presence of 
heparin-like molecules (48-50). Neither aFGF nor bFGF can bind high affinity FGF 
receptor in heparin or heparan sulfate deficient cells, while the mutant phenotype has 
been shown to be inverted if heparin is added. Furthermore, heparin is suggested to be 
possibly directly attached to the FGF receptor by the identification of a proteoglycan 
which has been shown to be the high affinity FGF receptor (51). Treatment of this 
proteoglycan with heparinase resulted in a receptor with lower molecular weight and 
4 
less binding affinity for FGF (51). 
To identify the specific functional domains on FGF that may bind the FGF 
receptor and heparin, a series of peptides derived from the bFGF sequence were 
synthesized (52). These bFGF derived peptides were tested for their abilities to inhibit 
bFGF binding to the receptor as well as their binding affinity for heparin. Peptides 
related to the sequences of FGF-(21-41) and bFGF-( 107 -116) were demonstrated to 
compete for bFGF binding to the receptor. In addition, these two peptides were also 
shown to inhibit thymidine incorporation into 3T3 fibroblasts when stimulated by 
bFGF, which further suggests the importance of these regions in receptor binding. In 
fact, more evidence supports the idea that the region of bFGF-(1 07 -116) is very likely 
to be directly involved in interacting with the FGF receptor. For example, Thr 113 of 
bFGF, which is located in this region can be phosphorylated by protein kinase A, and 
the phosphorylated bFGF displays an enhanced binding affinity for the FGF receptor 
(53). Additionally, although the members of the FGF family are highly homologous, a 
high frequency of sequence insertions or deletions have been observed in the region 
of bFGF-(107-116) (Figure 1.1). For example, between bFGF amino acids 112 and 
115, aFGF and KGF have two and four more residues than bFGF. Because various 
FGFs exhibit different binding affinities for the FGF receptors, it is likely that 
receptor binding specificity is related to these insertions and deletions. 
Since heparin plays a necessary role in FGF binding to its receptor (48-50), 
understanding the interactions between FGF and heparin is also critical for 
understanding the receptor binding mechanism by FGF. Chemical modification and 
thrombin digestion (54-56) studies have implicated that lysine 118 and Arg 122 of 
aFGF may be involved in heparin binding. Further, bFGF related peptides from this 
region containing the residues after 94 have been shown to bind heparin (52). A 
similar result supporting the importance of the carboxyl terminal region in heparin 
binding was obtained by using a series of genetically truncated bFGF (57). In 
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addition, the primary sequence of FGF reveals that there is a region in the C-terminus 
rich in positively charged amino acids. There are five lysines and arginines clustered 
around lysine 126 in bFGF whereas there are seven lysines and arginines in aFGF. It 
is very likely that these positively charged residues may play an important role in 
heparin binding. 
In addition to facilitating FGF binding to the tyrosine kinase receptor, heparin as 
well as other polyanions reveal the ability to protect FGF from thermal, acidic and 
proteolytic degradations (58, 59). FGF has been found to be surprisingly unstable at 
physiological temperatures but appears to be more stable in vivo, probably because of 
complexation to polyanionic molecules such as heparin or heparin-like molecules 
(60). The stabilization effect of polyanions on FGF has further been shown by the 
observation that aFGF appears to require lower energy for refolding in the presence of 
polyanionic molecules such as heparin, inositol hexasulfate and A TP (61). Heparin is 
primarily present on the cell surface and in the extracellular matrix (ECM). Indeed, 
endogenous bFGF has been found associated with heparin and heparin-like molecule 
such as heparan sulfate in the ECM (62-64), and addition of heparinase to ECM 
results in the release of FGF from ECM (65). Furthermore, the ECM has been 
implicated as a source of FGF for long-term stimulation of DNA synthesis for a 
variety of cells (66). These findings suggest that the ECM may serve as a reservoir of 
stored FGF. Because aFGF and bFGF are not secreted due to the lack of signal 
peptide sequences, the storage and release of FGFs from the ECM may be an 
important regulatory mechanism of FGF activity. 
Based on these observations, various mechanisms have been proposed to explain 
the partition of heparin or heparin-like molecules in regulating FGF activities. These 
include that 1) heparin may function to stabilize the tertiary structure of FGF; 2) 
binding of heparin may trigger a conformational change in FGF so that FGF can bind 
the FGF receptor with high affinity; 3) binding of FGF to heparin may facilitate FGF 
6 
oligomerization which is necessary for FGF receptor dimerization. In fact, evidence 
has been observed for all these possible models. While it has been discussed that FGF 
can be stabilized by heparin as described above, the binding of heparin to bFGF but 
not aFGF has been reported to induce a small but highly reproducible conformational 
change as observed in the amide I region of the protein's infrared spectrum (67, 68). 
Furthermore, FGF dimerization has also been demonstrated recently by a cross-
linking experiment with the presence of heparin (69). For further examination of these 
possibilities, a three-dimensional structure of FGF complexed with heparin is really 
necessary. 
After binding of FGF to the receptor, FGF is internalized by receptor-mediated 
endocytosis (43, 70). The detection of translocation of intact FGF into the cell nucleus 
led to the discovery that the amino terminus of FGF is a nuclear translocation 
sequence (71). A truncated form of FGF without the N-terminus fails to stimulate 
DNA synthesis and cell proliferation, though tyrosine kinase activity is observed to be 
induced after FGF binding to the receptor. It was further shown that when the FGF N-
terrninus is replaced with another nuclear translocation sequence such as that of yeast 
histone 2B, the chimeric FGF exhibits a comparable activity to the native protein 
(71). After nuclear translocation, FGF is involved in the transcriptional regulation of 
at least two genes (72). Although the detailed interaction of FGF with the genes 
awaits further investigation, this is the first time that a peptide growth factor has been 
reported to be directly involved in the gene-specific transcription. 
To better understand the signal process triggered by FGF, crystallographic studies 
of FGF have been carried out by us since 1989. A three-dimensional structure of FGF 
can provide not only a structural understanding of the receptor binding mechanism by 
FGF and other similar peptide growth factors, but also can provide a solid basis for 
the rational designs of drugs to either promote or inhibit FGF activities. It has been 
demonstrated that the oncogenes int-2, hst, FGF-5 and FGF-6 are expressed in many 
7 
transformed cells such as those of lung cancer and breast cancer (73) and the 
significance of the FGF family for malignant transformation is further indicated by 
the finding that, after genes from the ras family, the hst gene is the most frequently 
encountered oncogene in transfection assays (16). More efficient anti-tumor strategies 
should possibly be devised based on the active site structure of FGF. On the other 
hand, FGF is a potential drug for tissue repair of burnt skin and stomach or duodenal 
ulcers (74). If FGF is used as a tissue growth promoting therapy, the stability of FGF 
inside cells is a crucial factor. Without disrupting FGF activities, this can be achieved 
either by changing FGF per se such as proper site-directed mutagenesis or by 
designing accessory molecules that can stabilize FGF by protecting it from acidic and 
enzymatic degradation. All those approaches rely heavily on an accurate three-
dimensional structure of FGF. Furthermore, recent studies have revealed that bFGF 
can prevent the death of lesioned cholinergic neurons (75), and Alzheimer's disease is 
connected with an increased level of expression and abnormal distribution of bFGF in 
brains (76). We anticipate our structural and functional studies of FGF will also help 
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2.1. Crystallization and preliminary diffraction studies of FGF 
The recombinant analogs of bovine aFGF (Ala47Cys, Gly93His) and human 
bFGF (Ser70Cys, Ser88Cys), which were expressed in E. coli, have comparable or 
even higher biological activities than the native forms (1, 2) and were used in our 
structural and functional studies. The factorial method (3) was employed for 
crystallization trials. The protein samples of 10 mg/ml aFGF in 20 mM Na Citrate 
(pH 5.6) and 13 mg/ml bFGF in 20 mM Na Citrate (pH 5.0) were used. 
Crystals of aFGF were obtained by vapor diffusion against 0.2 M (Nf4)2S04, 2 
M NaCl, 0.02 M sodium potassium phosphate and 0.1 M sodium citrate at pH 5.6 
(Figure 2.1 ). The protein droplet contained equal volumes (3 J.ll) of the reservoir 
solution and a 10 mg/ml protein solution. The typical aFGF crystal is about 0.5 x 0.5 
x 0.5 mm3 in size and diffracts to approximately 2.5 A resolution. The crystals stop 
growing after about one month with fresh protein samples, but it takes much longer 
for old protein samples to grow to the optimal size. This may be due to an increased 
amount of dimeric arising from formation of intermolecular disulfide bonds. 
Precession photographs showed that the crystals are trigonal with space group P3t21 
(or its enantiomorph P3221) with unit cell edges of a = b = 78.6 A, c = 115.9 A 
(Figure 2.3). The Matthews coefficient calculation (4) indicated that there may be 
three aFGF molecules per asymmetric unit. 
Crystals of bFGF were also obtained by S. Faham using the hanging drop method. 
The precipitant solution contained 25% polyethylene glycol 8000 and 0.1 M Hepes at 
pH 7.6 (Figure 2.3). The crystals grow in the triclinic space group P1, with unit cell 
dimensions of a= 31.1 A, b = 33.5 A, c = 37.0 A, a= 64.2o, ~ = 106.40, y = 103.3° 
and diffract to about 1.9 A (Figure 2.2). Crystals of bFGF used for data collection are 
typically larger than 1 mm x 0.4 mm x 0.4 mm. 
2.2. Heavy atom derivative search for aFGF crystals 
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The multiple isomorphous replacement (MIR) method was used to obtain phase 
information. Heavy atom derivatives were screened by soaking aFGF crystals in 
different heavy atom reagents at various concentrations. Because no satisfactory 
synthetic mother liquor was found for the aFGF crystals, heavy atom reagent 
solutions were injected directly into the hanging drop with a 10 ~1 syringe. Typical 
volume was about 0.3 ~1 of heavy atom solution added to 6 ~1 crystallization drop. 
The screening of heavy atom compounds was carried out by comparing diffraction 
intensities on precession photographs of the soaked crystals with precession 
photographs of the native crystals. Table 2.1 lists the heavy atom compounds that 
were screened for aFGF. 
2.3. Area detector data for aFGF 
All diffraction data for the aFGF structure determination were collected at room 
temperature on a Siemens area detector mounted on a Siemens rotating anode 
generator operating at 50 KV x 90 rnA. CuKa radiation (A.= 1.54 A) was used for the 
diffraction studies. Crystals were sealed in the capillaries in equilibrium with several 
microliters of a high salt synthetic mother liquor (1000 ~1 of such a solution consists 
of 750 ~14M NaCl, 80 ~1 (NJ4)2S04, 8.0 ~14M NaKP04, 150 ~1 1.0 M Na Citrate 
at pH 5.6 and 12 ~1 H20) in which crystals can survive for several days. The crystals 
were mounted with a random orientation in capillaries. Data collection for these 
crystals started at a random Q angle and stopped after scanning 100°. The n scan was 
repeated after phi was changed by 90°. The collected data sets were autoindexed, 
integrated, scaled and reduced with the XENGEN software package (5, 6). Table 2.2 
lists the data statistics for the native and the derivative crystals which were soaked in 
4 mM EMTS and 3.3 mM K2PtC14 for 12 hours and 3 days, respectively. 
2.4. Heavy atom binding sites in aFGF 
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After both native and derivative data sets are available, heavy atom sites can be 
located by the difference Patterson function if the derivatives are isomorphous with 
the native crystal. All the derivative data sets were locally scaled to the native with 
the ROCKS program (7) before the difference Patterson maps were calculated. The 
difference Patterson for EMTS was very clear as illustrated for the Harker section w = 
1/3 (Figure 2.4A). Similar results were obtained for the anomalous difference 
Patterson (Figure 2.4B). The difference Patterson for K2PtCl4 is noisy and the 
anomalous signal can barely be observed (Figure 2.5). 
In either space group P3t21 or P3221, the asymmetric unit is one sixth of the unit 
cell and by convention it is located between x = (0, 1), y = (0, 1) and z = (0, 1/6). But 
because of the origin ambiguity on z, only x = (0, 1), y = (0, 1) and z = (0, 1/12) needs 
to be searched for self vectors while z = (0, 1/6) is needed for cross vectors because of 
the fixed origin. In order to find the heavy atom binding sites of EMTS and K2PtCi4, 
half of the Patterson function unit cell was searched with PSP (program written by B. 
T. Hsu). The peak height output by PSP does not take symmetry into account, which 
means in P3t21 or P3221, all points on the two fold axis will be doubled. After these 
factors were considered, one and two binding sites for EMTS and K2PtCi4 derivatives 
were found, respectively (Table 2.3). One binding site (0.53, 0.35, 0.023) was found 
to be the same for the two derivatives, implying that a common origin is used. 
2.5. Phase calculations and phase extensions for aFGF 
With the heavy atom binding sites available, the multiple isomorphous 
replacement phases were calculated and refined with PHARE (8). The phase 
possibilities for centric reflections in space group of P3t21 are shown in Table 2.4. 
With anomalous scattering information of the EMTS derivative incorporated, the 
refinement showed an increased phasing power of the anomalous derivative, 
confirming that the space group is P3t21 instead of the enantiomorph P3221. The 
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difference Fourier map showed additional minor binding site for the K2PtCl4 
derivative after 8 cycles of heavy atom site refinement (fable 2.5). The overall figure 
of merit is 0.68 to 3.0 A (Table 2.6). 
To improve the quality of the MIR electron density map, two phase extension 
methods were applied: solvent flattening and noncrystallographic symmetry 
averaging. For solvent flattening, programs from the CCP4 suite were used (9). The 
sphere radius for generating the envelope was chosen as 10 A. The solvent content 
was initially set to 40% due to the uncertainty about how many molecules were in one 
asymmetric unit. The protein envelope was generated automatically by B. C. Wang's 
method (10) and then applied to the MIR electron density map. Solvent flattening 
converged after six cycles. The solvent-flattened phases combined with MIR phases 
were used to generate another molecular envelope and applied to the MIR map again. 
This was repeated until convergence was achieved. After solvent flattening, the 
electron density map showed that there may be two molecules in one asymmetric 
unit. Using the value of 1 daltonJA3 for protein density, it was predicted that the 
solvent content of the unit cell was 60%. Using a solvent content of 55% (instead of 
60% to be sure that no protein electron density was cut off), solvent flattening of the 
original MIR map was repeated. The final phase angle changes of noncentric and 
centric reflections at 3 A were 34.90 and 12.20, respectively. 
Although the solvent flattened map clearly shows the molecular boundaries, it 
was still not possible to trace the backbone of the protein. To further improve the 
map, molecular averaging was carried out. Because the self-rotation function did not 
show how the two molecules in the asymmetric unit are related to each other, two P1 
cells were made to include each molecule from the solvent flattened map. Cross 
rotation functions (11) were then calculated based on the structure factors converted 
from these two P1 cells. The resultant peak shows these two molecules are related to 
each other by a general transformation with the three spherical polar angles of 45.00, 
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82.0° and 165.0°. Using these angles, the relative translation between the two 
molecules was determined by skewing the density of one molecule to the same 
orientation as the second, followed by calculation of a real-space translation function 
with the use of Fourier coefficients LJF0 (-h)F5 (h)]exp(-21tihu) where F0 and Fs 
h 
are the complex structure factors for the observed and skewed structures. The non-
crystallographic symmetry was further refined by maximizing the density correlation 
coefficient (12). 
With the refined noncrystallographic transformation matrix, initial electron 
density averaging between the two molecules was carried out (13) using the 
molecular envelopes generated by B. C. Wang's method (10). Due to the close 
contacts between the two molecules, the molecular envelopes generated by this 
method overlapped with each other in space and therefore were adjusted manually. 
After averaging, the R factor between FobsS and FcaJcS which were calculated from the 
symmetry averaged electron density map, dropped from 43.0% to 19.8%. The 
electron density map calculated with 2F0 - Fe coefficients and the averaged phases 
was obviously much improved and chain tracing became possible (Figure 2.6). 
2.6. Model building and refinement of aFGF 
The positions of the alpha carbon atoms were initially determined from sections 
of the averaged map stacked on acetate slabs. Ninety one Cas were roughly located 
and displayed on a Silicon Graphics workstation using the TOM/FRODO program 
(14). After polyalanine models of the two aFGF molecules were built, refinement of 
the model with PROLSQ (15) and phase recombination of the model phases with the 
averaged phases was carried out. The initial aFGF model was built based on the 
averaged maps. Because the averaged map had some loop regions truncated due to the 
size of the initial molecular envelope, averaging was carried out again with a 
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molecular envelope generated by putting 3 A spheres on each atom of the initial 
model. Using the new envelope, averaging converged at an R factor of 18.3% to 3 A 
resolution. After more cycles of model building, refinement and phase combination, 
residues 1-137 and 10-137 for the two aFGF molecules in the asymmetric unit were 
built into the electron density map. The last three carboxyl terminal residues are 
disordered in both molecules and the amino terminus of one aFGF is also disordered. 
Refinement of this model between 8- 2.7 A resolution yielded an R factor of 20.9%, 
with root-mean-square deviations from ideal bond distances and angles of 0.02 A and 
3.8° respectively. A total of 35 water molecules were located by difference Fourier 
calculations and added to this aFGF model. Refinement with XPLOR (16) of this 
model which has 2009 nonhydrogen atoms progressed to the final R factor of 17.7% 
with r.m.s. deviations from the ideal bond distances and angles of 0.012 A and 2.3° 
respectively. The structure coordinates have been deposited in the Protein Data Bank 
(lBAR.AFGF.PDB). The two aFGF molecules have about 98% and 91% complete 
structures respectively. 
2.7. Structure determination and refinement of bFGF 
The same heavy atom derivatives, EMTS and K2PtC4, were used in the bFGF 
structure determination by S. Faham and B. T. Hsu. Crystals of bFGF were soaked in 
a synthetic mother liquor (30% PEG8K, 0.1 M Hepes, pH 7.5), containing either 3 
mM EMTS or 5 mM K2PtC4 for 2 days (Table 2.7). Using the aFGF model, the 
heavy atom binding positions in bFGF crystals were located by difference Fourier 
map with the molecular replacement phases of aFGF. There is one EMTS binding site 
and 4 K2PtCl4 binding sites on bFGF. Isomorphous replacement phases were 
calculated to 2.8 A with an overall figure of merit of 0.62. The MIR map revealed 
similar molecular folds with aFGF and residues 20 to 144 of bFGF were subsequently 
fitted into the electron density map by A. J. Chirino. The first 19 and the last 6 bFGF 
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residues are disordered. Refinement of the bFGF model with a total of 40 water 
molecules with XPLOR programs by A. J. Chirino led to the final R factor of 17.0% 
between 5- 1.9 A resolution. The r.m.s. deviations of bond length and bond angle are 
0.015 A and 2.3° respectively (lBAS_BFGF.PDB). 
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Table 2.1. Heavy Atom Compounds Tested 
Compound Concentration Soaking time 
EMTS 4mM 12 hrs 
K2PtC14 3.3mM 7 days 
K21rCl6 20mM 7 days 
K2Pt(CN)4 1.6mM 14 days 
PtPOP 1.5mM 14 days 
K2U02F5 4mM 4days 
Hg(Ach * 12 days 
Pb(Ach 1.6mM 16 days 
Hg(Phh 2.9mM 9 days 
Nal 12.5mM 3 days 
PCMBS ** 6days 
Meurbromin *** 3 days 
EMP 0.8mM 3 days 
AuCl3 l.OmM 3 days 
* 0.3 ~1 of 1/4 saturated Hg(Ac)2 solution was added to the hanging drop. 
** 0.3 ~1 of 1/2 saturated PCMBS solution was added to the hanging drop. 
*** 0.5 ~1 2% Murbromin solution was added to the hanging drop 
EMTS: Ethyl Mercuri thiosalicylate 
EMP: Ethyl Mercury Phosphate 
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Table 2.2. Summary of the aFGF Area Detector Data 
reflections reflections 
resolution unique collected completeness R-factor 
Native 2.7 A 12,574 25,107 85% 4.4% 
EMTS 3.2A 7638 25675 93% 6.7% 
K2PtC14 3.2A 7179 23836 88% 7.9% 















Table 2.4. Centric Zones for P3t21 
Old 
0° or 180° 
60° or -120° 
120° or -60° 
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hOI 
0° or 180° 
120° or -60° 
60° or -120° 
Table 2.5. Refined Heavy Atom Sites 
X y z Occupancy B (A-2) 
EMTS 0.545 0.343 0.0147 0.475 27.5 
K2PtCi4 0.873 0.116 -0.0458 0.381 37.2 
0.557 0.353 0.0179 0.248 36.4 
0.150 0.548 0.145 0.115 51.1 
Table 2.6. Phasing Power of the Derivatives 
Resolution 11.1A 8.3A 6.4A s.2A 4.4A 3.8A 3.4A 3.oA overall 
EMTS 2.13 2.07 2.53 2.07 1.79 1.75 1.74 1.47 1.88 
EMTSanom 2.43 1.94 1.50 1.53 1.06 0.89 0.73 0.42 0.90 
K2PtCi4 1.08 1.66 1.75 1.71 1.27 1.08 0.87 0.66 1.17 
27 
Table 2.7. bFGF Heavy Atom Refinement Statistics 
Data Reso- Concen- measured comp- Rsym Refined fHIE 
lution tration reflection lete (%) Sites 
Native 1.9 A 8,462 89% 4.8 
EMTS 2.8A 3mM 2,745 87% 5.8 1 2.0 
K2PtC14 2.8A 5mM 2,877 91% 8.2 4 2.2 
Rsym = LII- <I >I/~) 
1 
fH /E=[Lf~ /L(Fderiv,obs -Fderiv,calc)2f2 
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Figure 2.1. An aFGF crystal grown under the high salt condition. 
Figure 2.2. bFGF crystals grown with the condition found by S. Faham (17). 
29 
Figure 2.3. Precession photograph (~ = l20) of the hOI zone of aFGF crystals. 
30 
u•e.v•e u•t eee 
V•l 000 
(A) 
u•e.v-e u•l eee 
(B) 
Figure 2.4. The difference Patterson (A) and difference anomalous Patterson (B) 
maps of EMTS in the Harker section w = 1/3. 
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u=e. v=e U=l 606 
V=l 006 
Figure 2.5. The difference Patterson map of KzPtC4 in the Harker section w = 1/3. 
32 
Figure 2.6. The 3 A averaged electron density map in the region of f3 strand 2. 
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Chapter 3 
FGF Structures and their Relationship to Biological Function 
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3.1. Architectural overview of the FGF structure 
The crystal structures of aFGF and bFGF reveal a very similar fold for the two 
proteins. With a roughly spherical shape of approximate 30 A in diameter, FGF 
contains 12 antiparallel ~ strands that are arranged in a pattern of approximate three-
fold internal symmetry as shown in Figure 3.1. Six of the strands form an antiparallel 
~ barrel, consisting of strands 1, 4, 5, 8, 9 and 12, numbered sequentially from the 
amino terminus. One end of the barrel is covered by the remaining six ~ strands, 
coupled in pairs so that the axis of the ~ barrel coincides with the molecular pseudo 3-
fold axis relating every 4 ~ strands (strands 1-4, 5-8 and 9-1 0). 
A striking feature of the aFGF and bFGF structures is the overall similarity to the 
folding pattern observed for the interleukin -1 a. and -1 ~ (ll...-1 a. and 1 ~). two growth 
factors that mediate the immune response (1-4). Despite the fact that IL-l~ has 
several more extended loops compared to FGF, superposition of FGF and interleukin-
1~ a.-carbon atoms of the 12 strands reveals a root-main-square deviation of only 1.5 
A (Figure 3.2). Recently, hisactophilin, which is an actin-binding protein (5), and a 
Kunitz-type trypsin inhibitor from Erythrina caffra seeds (6) have been found to also 
consist of 12 antiparallel ~-strands. This unusual fold was first observed in the 
structure of soybean trypsin inhibitor determined about twenty years ago (7, 8). 
Interestingly, although they possess quite different biological functions ranging from 
growth factors to protease inhibitor, these similarly folded polypeptides have the 
common feature of being involved in recognition of other proteins. 
In spite of the structural similarity, sequence comparison of these proteins with 12 
anti parallel ~ strands reveals very low sequence homology. For instance, human 
aFGF and interleukin-1 ~ are only 12% identical and 33% similar. In addition, the 
protein internal sequence symmetry correspondent with the pseudo three-fold axis can 
not be detected using the programs in the University of Wisconsin GCG package. 
Nevertheless, when the sequences of these proteins are aligned based on the three-
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dimensional structures, it is found that the hydrophobic character of residues at nine 
positions in the Jl sheets (residues 14, 23, 31, 56, 65, 73, 97, 109 and 117 of aFGF) is 
quite well conserved (Table 3.1 ). The crystal structures further demonstrate that the 
conserved residues form a compact core inside the protein, suggesting a unique role 
of these conserved amino acids in the protein folding (Figure 3.3). 
3.2. Structural comparison of the two aFGF molecules in one asymmetric unit 
Because the aFGF structure was determined using the crystals containing two 
aFGF molecules in one asymmetric unit, these two protein molecules were built and 
refined independently (9). An obvious difference between the two structures is that 
the first nine residues of one aFGF is disordered whereas the amino terminus of the 
second aFGF has well defined structure. Except that, superposition of the two aFGFs 
shows that they have quite similar backbone and side chain conformations, with an 
r.m.s. deviation of less than 0.56 A for the 126 common a-carbons (Figure 3.4). The 
quantitative comparison of the two structures illustrated in Figure 3.6 further indicates 
that there are only three local regions where the structural discrepancy is over 1.0 A. 
The most structurally variable region is around aFGF glutamine 77 where the 
difference is as large as 1.6 A. Located on one of the longest FGF loops between Jl 
strands 7 and 8, glutamine 77 and its adjacent residues are fairly exposed to a large 
solvent channel inside the crystal. Usually protein loops are flexible and the different 
conformations observed here may reflect a dynamic picture of FGF in solution. 
The second largest structural difference occurs near glutamate 91 of the Jl turn 
between strands 8 and 9. Unlike Gln 77, this is due to a lattice contact in the crystal. 
One aFGF has two amino acids located adjacent to Glu 91, Asn 92 and Tyr 94, which 
are in contact with Glu 49 of a neighboring molecule. For the other aFGF, the main 
chain carbonyl groups of Glu 91 and Gly 93 are hydrogen bonded to the neighboring 
residues Arg 88 and Lys 101, respectively. Lastly, the third site of a relatively large 
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structure variance is also caused by a lattice contact, where the aFGF residue 
glutamate 49 forms an intermolecular hydrogen bond to tyrosine 94 of the 
neighboring molecule. 
Molecular packing inside crystals can affect the main chain conformations as well 
as the side chain conformations. For example, superposition of the two aFGFs shows 
that the side chains of tyrosine 55 are quite different (Figure 3.5). Lattice contact 
analysis shows that while Tyr 55 of one aFGF does not interact with its neighboring 
molecules, Tyr 55 of the second aFGF in the asymmetric unit is however situated at 
an intermolecular interface and interacts with its neighboring molecule. 
Consequently, the two residues Phe 75 and Pro 65, which are adjacent to Tyr 55 and 
have hydrophobic interactions with Tyr 55, also display different conformations in 
the two structures. 
For further structural comparison, temperature factor analysis was performed for 
the two aFGFs. The temperature factor plot for the two molecules illustrated in Figure 
3.7 shows that although the rough trends of the temperature factor for the two 
molecules are similar, one molecule has generally higher temperature factors than the 
other, and further, several local regions display large fluctuations. This is consistent 
with the calculated average temperature factors, which are 26.7 A2 and 22.7 A2 for 
the two aFGFs respectively. Systematic analysis of the intermolecular contacts within 
4 A between symmetry related molecules shows that the aFGF molecule with lower 
average temperature factor has 13 residues involved in non-covalent contacts with its 
neighboring molecules. In contrast, none of the amino acids of the aFGF with a 
higher average temperature factor interacts with adjacent protein molecules. This 
suggests that lattice contacts are probably responsible for the overall temperature 
factor difference. Also, in addition to the overall temperature factor difference, local 
regions near residues 49 and 72 are shown to have relatively large difference in 
temperature factors. These differences are also mainly due to the lattice contact effect 
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(Figure 3.7). The Glu 49 region, which displays structural differences in the two 
aFGFs, has been discussed above. And one of the two leucines 72 in the two 
structures is also seen interacting with residue 126 of a neighboring molecule inside 
the crystal. 
Because the aFGF structure has been determined to 2.7 A, only 37 water 
molecules have been located for the two aFGFs in the asymmetric unit. These thirty 
seven water molecules are nevertheless unevenly distributed between the two protein 
molecules. Thirteen and twenty-four water molecules are bound to the two aFGFs 
respectively. Superposition of the two aFGFs further showed that while most interior 
water molecules were at common positions in both structures, the exterior water 
molecules are often different. Among the 7 common water molecules in both 
structures, five of them are located inside the protein and only two are bound on the 
protein surface. Furthermore, the four buried water molecules are found to bind the 
main chain amino and carbonyl groups from different 13 strands, whereas one buried 
water molecule is found to form a hydrogen bond with the buried side chain of Ser 99 
(Table 3.2). 
In general, the two aFGF molecules in the asymmetric unit have very similar three 
dimensional structures and the few observed local structural differences are mainly 
due to the lattice contact effect. In addition, interactions between the neighboring 
molecules packed inside the crystal may also be responsible for the overall 
temperature factor difference in the two structures. The structural similarity of the 
different molecules in one asymmetric unit is further supported by the commonly 
situated interior water molecules which have been independently located. The close 
conformations of the two aFGFs not only assures the correctness of the structure, but 
also simplifies the structural comparison between acidic and basic FGF. 
3.3. Structural comparison between aFGF and bFGF 
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With 55% sequence identity and 70% similarity, it is not surprising that acidic and 
basic FGF have very similar three dimensional structures. Superposition of aFGF and 
bFGF shows an overall r.m.s. difference of 0.74 A between the corespondent 126 Ca 
atoms (Figure 3.8). Furthermore, the structure similarity of aFGF and bFGF is not 
only contained in the 13 strands but also in virtually all the loops. In addition, despite 
the different resolutions, many of the bound water molecules are commonly observed 
in the two structures (9). Although forty ordered water molecules are located in 
bFGF, only thirteen and twenty four water molecules are found for the two aFGFs in 
the asymmetric unit respectively. Yet seven water molecules, that are common in the 
two aFGF structures in one asymmetric unit, have also common positions in bFGF. 
Similar to aFGF, four out of the five interior water molecules function to mediate the 
interaction between different 13 strands (Table 3.2) while one buried water molecule 
interacts with bFGF Ser 109. 
In spite of the overall structure similarity of aFGF and bFGF, there are several 
local regions that do display conformational difference between the two structures 
(Figure 3.8). The most variant region is around Ser 114 of bFGF or Glu 104 of aFGF 
where the a-carbon position difference is as large as 4 A. The crystal structures reveal 
that bFGF Ser 114 is located at the end of the long loop between 13 strands 9 and 10 
while at the same region aFGF has two more inserted residues (Lys 105 and His 106) 
than bFGF before 13 strand 10. Thus it leads to the dramatic conformational change of 
aFGF Glu 104 as shown in the Figures 3.8 and 3.9. 
Besides the large conformational difference revealed in this amino acid insertion 
site, there are three additional regions that have obviouly structural differences. They 
are localized around bFGF residues Pro 37, Ser 70 and Ser 101 (Figure 3.9). Unlike 
the regions of aFGF Glu 104 or the homologous residue of Ser 114 in bFGF, which 
have intrinsic structural differences, the conformational difference of these three 
regions are all due to lattice contact effects. For example, while aFGF Glu 28 is in 
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contact with Arg 128 of a neighboring molecule, its corresponding amino acid Asn 38 
in bFGF nevertheless interacts indirectly with Asn 105 of an adjacent bFGF through 
another residue Arg 40. Also, Asn 72 and Ser 101 of bFGF are both located at the 
molecular interface and interact with Leu 131 and Tyr 125 respectively. In contrast, 
aFGF Gly 62 is not involved in any lattice contacts and aFGF Glu 91 interacts with 
Glu 187 from a neighboring molecule. 
Therefore when lattice contact effects are excluded, aFGF and bFGF do have 
quite close three-dimensional conformations, except for the loop between strands 9 
and 10 in which the sequence insertion occurs in aFGF. The structural similarity of 
acidic and basic FGF demonstrated here is in agreement with the biochemical studies 
that a similar but slightly different activity profile for aFGF and bFGF has been 
reported. This will be discussed further in the following sections. 
3.4. The cysteine locations revealed in the FGF structures 
There are three cysteines in aFGF and four in bFGF, with two of them conserved 
in all species of aFGF and bFGF (aFGF Cys 16, Cys 83 and bFGF Cys 26, Cys 93). 
While alkylation of aFGF after reduction was reported to have no effect on mitogenic 
activity (13), a contrasting result was obtained by Harper et al. suggesting that a 
disulfide bond between Cys 16 and Cys 83 could be formed in aFGF (14). For bFGF, 
substitution of cysteine -70, -88 and -93 with serines by site-directed mutagenesis was 
reported to result in unaltered FGF activities, which implies that the disulfide bridge 
in bFGF is not functionally important (15-17). 
The double mutant Ala47Cys, Gly93His aFGF analog has been shown to possess 
a comparable or slightly higher mitogenic activity than the native (18). The locations 
of cysteines -16 and -83 as well as alanine 47, the substitution for cysteine-47, are 
explicitly defined in the three dimensional structure of this analog (9) (Figure 3.10). 
Cys 16 is located on the loop between J3 strands 2 and 3 while Ala 47 and Cys 83 are 
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located on the ~ strands 4 and 8 respectively. Interestingly, the cysteine localized on 
the loop structure is totally buried whereas the cysteine or the cysteine substitution 
located on the ~ strands are exposed. The exposure of Cys 83 in the three dimensional 
structure of aFGF is in agreement with the observation that EMTS binds aFGF near 
Cys 83. Furthermore, it is shown in the crystal structure that the distance between 
residues 47 and 83 is about 11 A while Cys 16 is situated relatively further away from 
these two residues by an approximate distance of 20 A. It is clearly indicated here that 
no pair of cysteine residues are in close enough proximity to one another to form an 
intramolecular disulfide bond. 
For bFGF, the structure of bFGF Ser70Cys and Ser88Cys analog, which has an 
equal activity to the native (15, 16), shows that residues -70, -88 and -93 are located 
on one side of the protein while cysteine-26 is buried at the other end (Figure 3.11). 
The shortest distance between these four residues is about 6.5 A, which is between 
amino acids 88 and 93. Residue 70 is situated about 18 A from 88 and 93 while Cys 
26 is located at least 20 A away from all the three residues. Therefore, like aFGF, it is 
quite certain that no intramolecular disulfide bridge can be possibly formed between 
these cysteines in bFGF. However, based on literature reports (20) as well as our 
observations that dimeric FGF can be detected with SDS-PAGE and HPLC, 
intermolecular disulfide bonds in both aFGF and bFGF appear to be possibly formed 
gradually between the exposed cysteines (i. e., cysteines-70, 88 and 93 in bFGF and 
cysteines-47 and -83 in aFGF). 
Since two disulfide bridges are observed in some structures of twelve antiparallel 
~ strands such as Kunitz-type trypsin inhibitor (5-7), the FGF cysteine positions are 
compared to that of trypsin inhibitor DE-3 from Erythrina caffra (ETI) (7). As 
revealed in the proteinase inhibitor structure, one disulfide bond is formed between 
the two loop residues cysteine-39 and -83 while the other disulfide bridge is between 
cysteines-131 and -139 located at the end of strand 9 and the beginning of strand 10. 
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Superposition of bFGF and ETI shows that the four cysteines in bFGF are neither 
overlapped with or close to the cysteines forming the disulfide bridges in ETI (Figure 
3.12). In general, the disulfide bonds of ETI, which has larger molecular dimensions 
( 44 x 40 x 40 A 3) (7) than FGFs, are located on the protein surface. 
3.5. Receptor binding studies 
Interest in FGFs have centered on the molecular details of the receptor-mediated 
pathways by which their diverse physiological activities are expressed. The 
knowledge of the interactions between FGFs and FGF receptors could provide 
valuable insights into the design of therapeutically useful agents which can either 
mimic or inhibit the action of the growth factor. In general, hormones can be 
classified into two groups based on their target receptors. The first class of hormone 
enters cells and binds a cytosolic receptor that is a transcription factor. Examples of 
this class of receptors are the steroid and thyroid receptors. The second class of 
hormone binds a receptor which is a transmembrane protein and a second messenger 
is usually coupled to the hormone and receptor interaction. Most peptide growth 
factors belong to the second class. Furthermore, some of these peptide growth factor 
receptors have seven transmembrane helices (such as the 13-adrenergic receptors and 
rhodopsin) and G proteins, cyclic AMP and ultimately protein kinases are involved in 
the signal transduction pathway. Others have a single transmembrane helix (such as 
PDGF and IL-2 receptors) and signal transduction is mediated through 
autophosphorylation of the intrinsic tyrosine kinase or the kinase associated with the 
receptors (19, 20). While many receptors of cytokines coordinating immune and 
inflammatory responses are non-tyrosine kinase proteins (such as the receptors of IL-
2, IL-3, IL-5, IL-6, GM-CSF, G-CSF and etc.) (20), other peptide growth factor 
receptors such as FGF receptors contain intrinsic tyrosine kinase domains. On the 
basis of their structural characteristics, tyrosine kinase receptors can be further 
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classified into three subclasses (20). These include the cysteine-rich monomeric 
receptor (class I), the cysteine-rich heterotetrameric a2!h receptor (class II) and the 
receptor with several extracellular immunoglobulin-like domains (class III). For 
instance, EGF receptors belong to class I while insulin receptors and FGF receptors 
belong to class n and m respectively. 
Binding of growth factors to their receptors often leads to receptor dimerization or 
oligomerization either by the binding of one monomeric ligand to two receptors 
simultaneously (such as human growth hormone (21)), or by binding of two 
monomeric ligands to two receptors (such as EGF (20)), or by binding of one bivalent 
ligand to two receptors (such as PDGF (20), NGF (22), TGF-13 (23), M-CSF (24)). 
For FGF, although it is a monomeric ligand, the receptor binding and dimerization 
mechanism has not yet been elucidated and some possibilities will be further 
discussed in chapter 4. 
The first FGF receptor eDNA was reported to be isolated in 1989 by using an 
oligonucleotide probe of a purified FGF receptor fragment (25). The amino acid 
sequence derived from this eDNA clone, which is a fms-like gene called fig (26), 
revealed that the receptor is composed of three extracellular Ig-like domains, one 
transmembrane helix and an intracellular tyrosine kinase domain with an approximate 
molecular weight of 130 kD. After this pioneering work, at least four more FGF 
receptors have been identified and cloned (25-36). Although these receptors are all 
encoded by fig and the related gene bek (26, 27), alternative RNA splicing has been 
shown to be possibly responsible for the observed multiple forms of FGF receptors, 
which can possess either two or three Ig-like domains, and different lengths of 
cytoplasmic tails (37). Furthermore, it appears that different FGF receptors have 
different binding specificities for the various members of the FGF family. For 
example, the KGF receptor, encoded by a gene closely related to bek (27), can bind 
with high affinity to KGF and aFGF but not bFGF (27). Sequence comparison shows 
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that the C-terminal 50 amino acids of the extracellular lg-like domain closest to the 
membrane are quite diversified in KGF and bFGF receptors (27). These 50 amino 
acids have now been further confirmed to be the major ligand binding specificity 
determinant by an elegant ligand-receptor binding study with chimeric receptors in 
which the last 50 amino acids are interchanged between different receptors (28). 
While details of the binding interactions between FGF and the last 50 carboxyl 
terminal amino acids of FGF receptor remain obscure, the crystal structure of FGF 
and the putative receptor binding sites allocated on this "3-D map" of FGF may 
provide some clues. 
Before the three-dimensional structure of FGF was determined, the possible 
receptor binding sites on bFGF had been explored with a series of bFGF derived 
peptides (38). On the basis of their ability to inhibit radiolabeled bFGF binding to the 
receptor and to stimulate thymidine incorporation, two functional subdomains were 
identified, which were bFGF-(25-69) and bFGF-(94-121 ). Shorter pep tides contained 
within these sequences, 31-51 and 107-116, were less effective but still exhibited 
similar activities. Interestingly, these two peptides however showed inconsistent 
mitogenic results in different cell lines. While bFGF-(31-51) had weak growth 
stimulation ability to 3T3 fibroblast cells, the same peptide was observed to inhibit 
the growth of vascular and capillary endothelial cells. For bFGF-(1 07 -116), although 
it showed quite potent agonist effects on 3T3 fibroblast cells, it had little effects on 
vascular and capillary endothelial cell growth. 
As demonstrated by the bFGF structure (9), bFGF-(31-51) covers from the 
beginning of 13 strand 2 to the end of the loop between 13 strand 3 and 4. Strands 2 and 
3 are adjacent, and are stabilized by interstrand hydrogen bonds (Figure 3.13). While 
most amino acids of 13 strand 2 are buried inside the protein in both aFGF and bFGF, 
13 strand 3 and the two 13 turns in this region are relatively more exposed on the 
protein surface (Figure 3.15B). Since a longer peptide of bFGF-(25-69) was shown to 
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have more potent mitogenic activity than bFGF-(31-51) (38), the conformations of 
the two peptides are therefore compared. Surprisingly, most additional residues in the 
longer peptide (residues 25-30 and 52-69) are not in contact with bFGF-(31-51) 
(Figure 3.14 ). The only interactions between residues after 51 and the region of 31-51 
are reflected in a hydrophobic core formed by Leu 33, lie 35 from bFGF-(31-51) and 
Leu 54, Leu 56, Leu 64, lie 66 from bFGF-(52-69). The additional six amino acids 
before 31, on the other hand, are observed to form a ~ turn which could stabilize the 
conformation of bFGF-(31-51) by forming two hydrogen bonds through the 
interactions of residues 26-31 and 29-45 respectively. 
The second putative receptor binding peptide, bFGF-(107-116) is located on a 
different face of bFGF from 31-51 as illustrated in Figure 3.16. Much evidence has 
strongly suggested that the region of bFGF-(107-116) is very likely to be directly 
involved in interacting with the FGF receptor. For example, in addition to the peptide 
mapping experiment which revealed the importance of bFGF-( 107 -116) in receptor 
binding (38), Thr 113 located in this region can be phosphorylated by protein kinase 
A, and the phosphorylated bFGF displays an enhanced binding affinity for the FGF 
receptor (39). Further, between bFGF amino acids 112 and 115, aFGF and KGF have 
two and four more residues than bFGF respectively, and the two oncogenes int2 and 
FGF5 have an additional 7 to 14 amino acids at the same region (Figure 3.17). In 
general, the FGF family is a highly homologous protein family with very rare 
sequence deletions and insertions. The high frequency of sequence insertion occurring 
here strongly suggests the functional importance of this region. 
Spanning ~ strands 9 and 10, bFGF-(107-116) and aFGF-(97-108) reveal a 
generally similar structural framework, but with a slightly different conformational 
loop. The two inserted residues in aFGF occur on the long loop which connects 
strands 9 and 10 so that the overall tertiary structure of 12 anti-parallel ~ strands is 
maintained (Figure 3.18). The ~ strands at this region are almost buried except the 
46 
partially exposed bFGF Trp 115. The long loop connecting the two strands is 
however quite exposed (Figure 3.19). The two adjacent basic residues located at the 
beginning of the loop, which are Lys 100, Lys 101 in aFGF and Arg 110, Lys 111 in 
bFGF, have perpendicular side chain conformations with the first basic residue 
relatively distant from the rest of the loop. The following residue in the sequence is a 
histidine in aFGF, but a tyrosine in bFGF. With both similar main chain and side 
chain positions, bFGF Tyr 112 is exposed to solvent while His 102 of aFGF is buried 
under the side chain of the inserted aFGF Lys 115. A very different solvent 
accessibility is observed again on the next residue in the two structures, which is an 
alanine in aFGF but a threonine in bFGF. The solvent exposure of bFGF Thr 113 is 
consistent with the result that this residue can be phosphorylated by protein kinase A. 
Following Thr 113 is Ser 114 in bFGF which is located at the end of the loop between 
strands 9 and 10 where a dramatic change of the backbone conformation occurs on 
the corresponding residue of Glu 104 in aFGF. aFGF Glu 104 is observed to swing 
out of the loop so that the two inserted aFGF residues Lys 105 and His 106 can be 
accommodated at the end of the loop. The more extended loop in aFGF leads to a 4 A 
deviation in the Ca positions at this place. 
Due to the overall architecture of the ~-stranded protein, there are many ~turns 
connecting adjacent strands in the FGF structure. However the loop between ~ strands 
9 and 10, which is likely to interact with the FGF receptors, does not belong in a 
typical ~ hairpin classification. Strands 9 and 10 do not have interactions with each 
other except near the loop region. Two hydrogen bonds are formed between the main 
chain amino and carbonyl groups on ~ strand 9 and 10 and form the narrow end of the 
n loop. There are five bFGF residues and seven aFGF residues located in this loop. In 
both structures, these amino acids are demonstrated to have such geometry that three 
sharp turns are formed inside this loop, resulting in a stable conformation where 
multiple polar interactions and hydrogen bonds are formed between the main chain 
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amide and carbonyl groups. The two additional aFGF residues are inserted in the third 
turn of the loop so that the overall geometry of the loop is maintained. The stability of 
the loop between J3 strands 9 and 10 shown here supports the observation that the 
peptide of bFGF-(107-116) alone can possess strong inhibitory activity to the receptor 
binding by FGF. Because most residues on J3 strands 9 and 10 are buried, the loop 
between the two strands is very likely to play an important role in receptor binding. 
To further confirm and characterize this receptor binding region, more biological 
studies, such as the site-directed mutagenesis of the amino acids located on the loop, 
need to be carried out. 
3.6. Nuclear translocation of FG F 
After binding of FGF to the receptor, the FGF and FGF receptor complex is 
internalized into cells by receptor-mediated endocytosis. Intact aFGF has been 
identified for up to six hours after it enters cells and degradation products of 10-KD 
and 15-KD can be detected inside the cell up to 24 hours (40, 41). Further, the 
presence of FGF in the cellular nucleus has been recently shown by 
immunohistochemical localization studies within mesenchymal cells (42). Nuclear 
import of polypeptides occurs by binding of the peptides to a nuclear pore complex 
that facilitates the translocation process. Specific sequences containing basic residues 
usually accelerate targeting of proteins to the nucleus (43). Based on the sequence 
characteristics of nuclear translocation of proteins, a peptide of aFGF-(7-13) 
containing the sequence NYKKPKL was identified to be similar to the nuclear 
translocation sequence of other nuclear proteins ( 44 ). It was further shown that a 
mutant aFGF lacking the putative nuclear translocation sequence failed to stimulate 
cellular DNA synthesis and cell proliferation, although it could still induce receptor 
tyrosine kinase activities. In addition, when the aFGF N-terminus was replaced by 
other nuclear translocation sequence such as that of yeast histone 2B, the chimeric 
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aFGF was reported to exhibit comparable mitogenic activities to the native protein 
(44). The significance of the presence of FGF in the nucleus was further investigated 
in a cell-free system of nuclear extract from Ehrlich ascites tumor cells. In this 
experiment, bFGF was demonstrated to regulate phosphoglycerate kinase gene 
transcriptions (45) and a 5' upstream region of the pgk gene was further demonstrated 
to be required for gene activation induced by bFGF. Therefore, it is likely that FGF 
may have direct interactions either with this DNA sequence or with other unknown 
cis-elements. 
The FGF crystal structure shows that the nuclear translocation peptide of FGF 
appears not to have a stable three-dimensional conformation. Of the two 
independently-determined aFGF molecules and the bFGF structure (9), the FGF 
amino terminus can only be observed in one aFGF molecule (Figure 3.20). The 
structure reveals that the peptide of aFGF-(1-9) possesses a rather extended form and 
does not specifically interact with the remainder of the molecule. Instead, it is 
stabilized by contacting neighboring molecules which are packed inside the crystal 
around it mainly through hydrophobic interactions. For example, Phe 1, Leu 3 and 
Pro 4 are clustered on one side of the amino terminal peptide and form a hydrophobic 
core by interacting with Phe 22, Tyr 15, Leu 133 and Leu 135 of a neighboring 
molecule. On the other side of the peptide, the side chain of Leu 5 is stabilized by 
interacting with Leu 55, Pro 64, Pro 79 and Leu 84 from another neighboring 
molecule. There are three closely located basic residues in the nuclear translocation 
peptide, lysines 9, 10 and 12. Both lysines 9 and 12 appear to be quite flexible and are 
disordered in the crystal structure, whereas the next basic amino acid, Lys 12, has 
defined side chain density, although it is quite exposed to solvent and has barely any 
interactions with other residues. As demonstrated here, the overall independence of 
the aFGF nuclear translocation sequence from the rest of the structure is consistent 
with the observation that the chimeric aFGF fused with other nuclear translocation 
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sequence maintains mitogenic activity. 
3.7. FGF binding to heparin 
FGF is a unique member of the peptide growth factor family in the sense that 
FGF is so far the only growth factor known to absolutely require heparin or heparin-
like molecule to bind its receptor (46-48). While many other growth factors such as 
GM-CSF, ll...-3, pleiotrophin, platelet factor 4, amphiregulin and heparin-binding-
EGF are known to be able to interact with heparin, and some of these including ll...-3 
and GM-CSF, are active only in the presence of heparin (49), the significance of 
heparin binding to these growth factors is still unclear. However for FGF, a series of 
recent biochemistry experiments have demonstrated that heparin is involved in 
modulating FGF activity in the first step of FGF action by facilitating FGF binding to 
its receptor. Yayon et al. showed that the binding ability of FGF to the FGF receptor 
was lost in the heparan-sulfate deficient cells while the mutant phenotype could be 
inverted if heparin or heparan sulfate was added (47). In addition, it was further 
pointed out by Sakaguchi et al. that heparin could be directly attached on the FGF 
receptor by the identification of a 150-kD heparan sulfate proteoglycan as a high 
affinity FGF receptor (46). They also showed that treatment of the heparan sulfate 
proteoglycan with heparinase resulted in a reduced molecular size of the receptor and 
decreased binding affinity of FGF for the proteoglycan, which further suggests that 
heparin-like molecules may play an obligatory role in the regulation of receptor 
binding of FGF. 
Besides regulating FGF binding to receptor, heparin also functions as a stabilizer 
of FGF and protects FGF from acid and enzymatic degradation (50,51). In addition, it 
also serves as a reservoir for storage of FGFs in the extracellular matrix (ECM) and 
release of FGF from ECM can be observed when heparinase or extra heparin is added 
(52). The size and the degree of sulfation in heparin, shown by many in vitro and in 
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vivo experiments, are the critical factors for heparin binding to FGF. Depolymerized 
heparin containing as little as 8-10 sugar units were demonstrated to be as effective as 
the whole heparin molecule for binding FGF or releasing FGF from ECM (53, 54). 
The sufficiency of a heparin octasaccharide for regulating FGF binding to the receptor 
is further supported by the recent FGF-receptor binding study with a soluble form of 
FGF receptor and a series of small heparin oligosaccharides of different lengths (55). 
For the sulfate groups, N-sulfate groups have been shown to be crucial for heparin 
binding to FGF while the presence of 0-sulfate groups appears to have an increased 
but not critical effect on heparin binding to FGF (53). 
Correspondent with the highly negatively changed groups on heparin (Figure 
3.21), a region rich in positively charged and polar amino acids is found in both aFGF 
and bFGF crystal structures (9-12). Lys 112, Lys 113, Asn 114, Arg 116, Lys 118, 
Arg 122, Gln 127, Lys 128 are clustered around Lys 118 in aFGF while Asn 28, Arg 
45, Lys 120, Arg 121, Lys 126, Lys 130 and Gln 135 are centered around Lys 126 in 
bFGF. Lys 118 of aFGF and Arg 126 of bFGF are located on ~ strand 11, which is 
adjacent but distinct from the putative carboxyl terminal receptor binding site (Figure 
3.22). The importance of the residues after Asn 103 for heparin binding in bFGF has 
been demonstrated in many biochemistry experiments. For example, in agreement 
with the studies with a series of genetically truncated FGFs (56), peptide bFGF-(103-
146) was demonstrated to possess binding affinity to radiolabeled heparin (38). 
Furthermore, reductive methylation, site-direct mutagenesis and thrombin digestion 
experiments have all implicated the importance of aFGF Lys 118 as well as its 
adjacent residue Arg 122 in heparin binding (57-59). 
To elucidate the exact binding site of heparin on FGF, we have been working on 
the crystal structure of FGF and heparin oligomer complex. The structure of FGF and 
heparin complex is also necessary to prove the hypothesis proposed by Yayon et al. 
that a vital conformational change of FGF induced by heparin is probably required for 
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FGF binding to the FGF receptor (47). Crystals of aFGF obtained in the presence of 
low molecular weight heparin by using the old aFGF crystallization conditions (9) 
appeared to exclude heparin from the crystals since the "cocrystal" morphology 
remained the same and no obvious peaks could be observed in the difference Fourier 
map. The reason that heparin is not included in the crystal is probably due to the 
heterogeneity of the heparin sample used in crystallization. Therefore, a homogenous 
heparin analog, sucrose octasulfate, was used for these studies and will be further 










































































































































































































































































































































































































































Table 3.2. Interactions between aFGF and the Buried Water Molecules 
Water Residue Strand Residue Strand 
H20 504 NH2S6 ~5 co 83 ~8 
H20 505 NH2 97 ~9 co 109 ~10 
H20 515 NH2110 ~10 co 118 ~11 
H20 520 NH223 ~2 co 14 ~ 1 
H20 517 Ser99 ~9 
* Water molecules are numbered as in 1BAR_AFGF. PDB. 
**. NH2 and CO are main chain amide and carbonyl groups that bind the water 
molecule. 
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Figure 3.4. The Ca backbone superposition of the two aFGF molecules in one 
asymmetric unit. 
~ro79 ~ro79 
Figure 3.5. An example of side chain conformational difference caused by lattice 
contacts in the aFGF crystal. Residues with thick and thin lines are from the two 
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Figure 3.8. (A). Stereoview of backbone structures of superimposed aFGF and bFGF. 
aFGF residue 104 is labeled. (8). Sequence alignment of bovine aFGF (top) and 




























































































































Figure 3.10. Locations of the three cysteines (residues 16, 47 and 83) present in the 
aFGF structure. 
Figure 3.11. Cysteine locations in the bFGF structure (shown with the same 




























































































































































Figure 3.13. Backbone conformation of bFGF-(31-51), the N-terminal putative 
receptor binding site. 
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YFLRILPDGTVDGTKDRSDQH 
FFLRIHPDGRVDGVREKSDPH 



















20 22 2A 
Residue Number 
(B) 
Figure 3.15. (A) Sequence alignment and (B) solvent accessible smface area of the 




































































KGF NTYASAKWTHNGGE ................ MFVALNQ 
95 
AFGF NTYISKKHA .... EKH .............. WFVGLKK 
104 
BFGF NTYRSRKYT .... S ................ WYVALKR 
INT2 NTYASRLYR .... TGSSGPGAQRQPGAQRPWYVSVNG 
FGF5 NTYASAIHR .... TEKTGRE .......... WYVALNK 
Figure 3.17. Sequence comparison of KGF, aFGF, bFGF, int2 and FGFS in the 
putative receptor binding region. 
Figure 3.18. Stereoview of the putative C-terminal receptor binding site. bFGF (thin 
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Figure 3.19. (A) Solvent accessibility comparison between aFGF and bFGF in the 
C-terminal putative receptor binding site. Interestingly, although aFGF has two more 
residues than bFGF at this putative receptor binding site, bFGF has a slightly larger 
solvent accessible area (318 A2) than aFGF (281 A2). (B) Sequence alignment of 










































































Figure 3.21. The major repeating unit of heparin. 
104 
Figure 3.22. The putative heparin binding site (shown with side chains in the region 
from residue 112 to residue 122) and receptor binding sites (thick lines) mapped onto 
the aFGF structure. 
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Chapter 4 
Interactions of FGF with Sucrose Octasulfate and an 
Implied Receptor Binding Mechanism 
77 
4.1. Introduction 
Although sucrose octasulfate has long been known to promote tissue repair, its 
therapeutical mechanism is unclear. Used in the treatment of stomach ulcers, sucrose 
octasulfate is unique in that the effectiveness appears not to involve an adjustment of 
the stomach pH (1). Based on its polyanionic property and its structural similarity to 
heparin disaccharide, Folkman et al. tested the binding affinity of FGF to sucrose 
octasulfate and found that it can bind sucrose octasulfate more tightly than it binds 
heparin (2). As with the FGF and heparin complex, bFGF bound to sucrose 
octasulfate remains stable even at low pH and exhibits enhanced mitogenic activity to 
various tissue ulcers (2). Recently sucrose octasulfate has been shown to induce the 
same small but highly reproducible spectroscopic changes in bFGF as heparin does, 
further suggesting that heparin and sucrose octasulfate interact similarly with bFGF 
(3). To better characterize the specific interaction between sucrose octasulfate and 
FGF, crystallographic studies of the FGF and sucrose octasulfate complex have been 
performed. In addition, the three-dimensional structure of sucrose octasulfate bound 
to FGF may provide a structural basis for understanding the binding of FGF to 
heparin as well as to its receptor in the presence of heparin. 
4.2. Structure determination of the aFGF and sucrose octasulfate complex 
Both the single (Ala47Cys) and double (Ala47Cys, Gly93His) mutant aFGF 
samples exhibit comparable mitogenic activity to the wild type and were used in 
cocrystallization trials. Low ionic strength precipitant solutions in the presence of 3.3 
mM sucrose octasulfate were used in the factorial screening (4). Cocrystals were 
obtained with both aFGF mutants by the vapor diffusion method. Hanging drops 
contained equal volumes of a 10 mg/ml protein solution and reservoir buffer (0.1 M 
MgCh, 27.5% PEG8K, 0.1 M ADA, pH 6.5 and 3.3 mM sucrose octasulfate). While 
only small crystals of the [Ala47, Gly93] aFGF analog were obtained using this 
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condition, the [Ala47] aFGF analog yielded crystals approximately 0.5 x 0.5 x 0.5 
mm3 in size with a trigonal morphology. The crystals of the [Ala47] aFGF analog 
were therefore used in the following structural studies. Precession photographs 
revealed that these crystals belong to the space group P3t21 or P~21 with unit 
dimensions of a = b = 55.3 A and c = 86.1 A. 
Intensity data were collected on a Siemens multiwire area detector mounted on an 
18-kW rotating anode generator and were indexed with the XENGEN programs (5). 
The cell constants provided by the autoindexing program were a = b = 110.6 A and c 
= 172.2 A, which were exactly twice of those obtained from precession photographs. 
Attempts to index the data using the initial small cell constants (a= b = 55.3 A and c 
= 86.1 A) failed to index a large fraction of the data, supporting the correctness of the 
XENGEN cell constants. Due to the larger dimensions of cell constants, the structure 
determination became more difficult. While the smaller unit cell contains only one 
protein molecule in one asymmetric unit, the larger unit cell contains eight molecules 
per asymmetric unit. 
Nevertheless, when the intensities of reflections were examined, the processed 
data showed a general pattern at low resolution of large intensities for reflections with 
even indices and small intensities for reflections with odd index (Table 4.1 ). Together 
with the observation that only the smaller cell constants were found on the precession 
photographs, it appeared that the crystal form with the larger unit cell could be 
thought of as containing the equivalent of eight smaller unit cells related 
approximately by translations of one half along the a, b, and c axes in the larger unit 
cell. Yet these are not exact relationships, otherwise all reflections with any odd index 
would have intensities exactly equal to zero. 
Because the reflections with odd index are much weaker than those with even 
indices, the molecular replacement search was first attempted in the smaller unit cell 
where there is only one molecule per asymmetric unit. A new data set was generated 
79 
by removing all reflections with odd h, k or 1, and dividing by a factor of two the even 
indices of the remaining reflections. The search model used in the molecular 
replacement was the 2.7 A resolution aFGF structure (Ala47Cys, Gly93His) 
previously determined in Rees' laboratory [Chapter 3 and (6)]. By using the 
reflections within the resolution of 5 - 8 A, a rotation function solution was obtained 
with the Patterson correlation refinement program (7). After the aFGF model was 
properly oriented, the translation search was carried out in both P3221 and P3I21 
because of the enantimorph ambiguity. The translation search in P3I21 yielded a 
solution with an R-factor of 44% (7.2 cr peak height), while for P3221 the best R-
factor obtained was 51% (4.6 cr peak height). The correct molecular replacement 
solutions were later confmned by the binding sites of heavy atom derivatives (see 
below). The Hg binding site of EMTS is just near the only exposed cysteine in the 
[Ala47] aFGF analog, whereas K2PtC4 was found to bind to His 124, His 106, and 
Arg 122. Furthermore, the heavy atom binding sites calculated in a difference Fourier 
map using the molecular replacement phases gave peaks that were consistent with the 
difference Patterson map. 
Although the difference Fourier electron density map calculated with the 
molecular replacement phases showed the heavy atom binding sites on aFGF, no 
obvious difference peaks corresponding to the bound sucrose octasulfate molecule 
were found. In addition, there was little density for the side chain of His 93, 
suggesting that the averaged structure in the smaller unit cell, though close enough to 
simplify the initial molecular replacement search, was not accurate for high resolution 
analysis. Therefore the whole cell was generated by translating the molecular 
replacement model along a, b and c by one half of the larger cell constants so that one 
asymmetric unit contained eight molecules. The space group also changed from 
P3I21 to P3221 when the c axis was doubled. Real space rigid body refinement 
against the EMTS single isomorphous replacement phases was then carried out using 
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TNT (8), which lowered the R-factor to 34.9% at 3.5 A resolution. Several more 
cycles of positional refinement further lowered the R-factor to 27.1 %. Using the 
phases from this model, an F0 - Fe map was calculated. Encouragingly, a large 
difference peak was found near Lys 118, possibly corresponding to the bound sucrose 
octasulfate. However the density was still not sufficiently resolved to unambiguously 
model the sucrose octasulfate. Therefore, to further improve the electron density, a 
second heavy atom derivative data set (K2PtCl4) was collected. The K2PtC4 binding 
sites were located in a difference Fourier map using the refined model phases. The 
MIR phases were subsequently calculated with HEAVY (9) by refining the heavy 
atom sites against the difference Patterson map (Table 4.2). These phases were then 
combined with the molecular replacement phases. Although the overall map quality 
improved slightly after phase combination, the regions near the His 93 side chain and 
sucrose octasulfate remained unchanged, probably due to the poor quality of the MIR 
phases. The figure of merit for the MIR phases was only 0.33 to 3.0 A (See Table 
4.2). 
To further improve the phases, eight-fold molecular averaging was carried out 
(10). The general noncrystallographic symmetry relations between the eight 
molecules in the asymmetric unit were obtained from the refined model. After a 
sucrose octasulfate molecule was roughly positioned according to the difference map, 
a molecular envelope was generated by placing 4.0 A spheres at each atomic position 
of sucrose octasulfate and 2.4 A spheres around each protein atom except those in 
residue 93. Since the search model has a glycine at position 93 (6), 6 A spheres were 
used for this residue. Phases were then iteratively refined by molecular averaging by 
starting from the MIR phases. Averaging at 3 A resolution converged to a final R-
factor of 22.5% between the FobsS and FcaJcS. The quality of the electron density map 
after averaging was greatly improved. This is exemplified by a region near His 93 
where no side chain density was evident before averaging (Figure 4.1). 
81 
In the averaged map, the six-membered ring of sucrose octasulfate has relatively 
well-defined density, while the five-membered ring is partially disordered. After a 
model of glucose tetrasulfate was fitted into the averaged map, iterative manual 
adjustments and positional refinement were performed. The electron density map 
phased by the combined model and averaged phases revealed improved density for 
the five-membered ring and some of the sulfate groups. After gradual addition of 
more sulfate groups and more cycles of positional and temperature factor refinement, 
the entire sucrose octasulfate was successfully modeled (Figure 4.2). The present 
model without solvent molecules has an R-factor of 20.4% using all the data to 2.7 A 
resolution. The r.m.s. deviations from ideal bond distances and angles are 0.016 A 
and 2.7°, respectively. 
4.3. Structure of the aFGF and sucrose octasulfate complex. 
Sucrose octasulfate binds aFGF in the region around Lys 118 (Figure 4.3), which 
is the largest region rich in positively charged residues in both the acidic and basic 
FGF crystal structures (6,11-13). The region of aFGF involved in sucrose octasulfate 
binding spans the residues from Lys 112 to Gln 127. In addition, one N-terminal 
residue, Asn 18, also interacts with the bound ligand. Overall, aFGF bound to sucrose 
octasulfate has a very similar backbone conformation to that of aFGF alone. 
Superposition of 126 a-carbons from the structures of aFGF and aFGF bound to 
sucrose octasulfate shows an r.m.s. difference of only 0.50 A. There are, however, 
some large side chain conformational changes in the sucrose octasulfate binding 
region. Arg 116 and His 124 are two such examples of residues whose side chains are 
moved for interacting with the bound sucrose octasulfate (Figure 4.4). 
The detailed interactions between aFGF and sucrose octasulfate are shown in 
Figure 4.5. Lysine 118 has the most intensive interactions with sucrose octasulfate, 
forming hydrogen bonds with two sulfate groups from the six-membered ring and 
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also form salt bridges to two more sulfate groups from the five-membered ring. In 
addition to Lys 118, Lys 112 is also hydrogen bonded with two sulfates from each 
sugar ring and interacts electrostatically with another sulfate. Surprisingly, the side 
chain of the adjacent residue, Lys 113, is disordered in the complex structure and 
does not seem to interact specifically with sucrose octasulfate. However, its main 
chain amide is hydrogen bonded to sucrose octasulfate. Another amino acid 
interacting with more than one sulfate group is Arg 122, which binds sucrose 
octasulfate through the two sulfate groups from the five-membered ring. Furthermore, 
in addition to these positively charged residues, amino acids Asn 18, Arg 116 and Gln 
127 are also involved in interactions with sucrose octasulfate. 
The overall structures of the eight protein molecules in the asymmetric unit are 
very similar. Each of the eight aFGFs binds to a single sucrose octasulfate except one 
which also has weak interactions with a neighboring aFGF. On the other hand, the 
eight sucrose octasulfate molecules bound to the eight aFGF molecules are however 
more diverse. Comparison of the eight sucrose octasulfate molecules based on the 
superposition of aFGF a-carbons shows that both the sulfate groups and the sugar 
rings, especially the five-membered ring, can adopt different conformations. 
Additionally, the orientation and position of sucrose octasulfate bound to aFGF also 
shows slight variation in the superposition (Figure 4.6). In spite of the differences 
discussed above, the protein residues and the sulfate groups of sucrose octasulfate that 
are involved in binding are in general similar in all the eight complexes, although 
some details of the hydrogen bonds and electrostatic interactions vary in different 
complexes of aFGF and sucrose octasulfate. 
Based on the sequence alignment of acidic and basic FGF, most residues of aFGF 
that are involved in binding to sucrose octasulfate are also likely to be involved in 
bFGF binding to sucrose octasulfate (Figure 4.7). The three aFGF basic residues that 
play critical roles in binding sucrose octasulfate are Lys 112, Lys 118, and Arg 122. 
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The analogous residues in bFGF are Lys 120, Lys 126 and Lys 130, respectively. 
Residues Asn 18 and Gin 127, which also contribute to sucrose octasulfate binding, 
are conserved in bFGF as well. The only nonconserved amino acid in aFGF binding 
to sucrose octasulfate is Arg 116, which is a glutamine in bFGF. Nevertheless, 
superposition of acidic and basic FGF suggests that the side chain amide groups of 
Gin 124 in bFGF and Arg 116 in aFGF could play an equivalent role in interacting 
with sucrose octasulfate. 
The crystal structure of the complex between aFGF and sucrose octasulfate 
described here is consistent with biochemical studies of FGF binding to heparin. The 
biological importance of the two basic residues Lys 118 and Arg 122, which are 
shown in the complex structure to be critical in interacting with sucrose octasulfate, 
have been previously reported. Reductive methylation of aFGF occurs mainly on Lys 
118 and yields 90% modification of this residue. The methylated aFGF exhibits a 
reduced binding capacity to heparin as well as a lower mitogenic activity to 
Balb/C3TL cells (14). Similar results were obtained by site directed mutagenesis 
when lysine 118 was replaced by a glutamate (15). Arginine 122, which is adjacent to 
Lys 118 in the tertiary structure, has been shown to be a thrombin cleavage site and 
its digestion can be blocked by the presence of heparin (16). By modeling in the 
major repeating unit of heparin to mimic sucrose octasulfate binding to aFGF, Glc(6-
0S03) and Ido(5-C(h) of heparin, but not Ido(2-0S03), appear to be able to make 
contacts with aFGF similar to those made by sucrose octasulfate. In addition, Glc(2-
NS03) is very likely to interact with more than two residues of aFGF simultaneously. 
This is consistent with the observation that N-sulfate groups are critical for heparin 
binding to FGF by using a series of depolymerized and size-homogeneous heparin 
oligomers (17). The evidence of the structural and biochemical similarity of FGF 
binding to heparin and to sucrose octasulfate shown here strongly suggests that the 
interactions between aFGF and sucrose octasulfate are likely to be applicable to the 
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understanding of the interactions between the heparin polysaccharide and FGF. 
Because of the different molecular size and degree of sulfation between heparin and 
sucrose octasulfate, additional heparin binding sites are likely to be present on aFGF 
and will be discussed further in the following sections. 
4.4. FGF binding to heparin polysaccharide 
The minimum size of heparin required for FGF binding has been extensively 
studied by many groups (17-19). Octasaccharides (i.e., eight sugar units) have been 
demonstrated to be the shortest fragment that can bind FGF and facilitate FGF 
binding to its receptor. Furthermore, it has been recently reported that bFGF can be 
cross-linked as a dimer with the addition of heparin oligosaccharides, suggesting 
dimerization of bFGF may occur in the presence of heparin (19). 
From fiber diffraction studies, heparin forms a helical structure with a repeat 
distance of approximately 17 A and four sugar rings per tum (20). Therefore a 
heparin octasaccharide bound to two FGF molecules should span a linear distance of 
about 34 A. In the cocrystals of the aFGF and sucrose octasulfate complex, there is 
only one type of aFGF dimer found in the crystal packing, where the bound sucrose 
octasulfate molecules could be replaced by a linear heparin helix without penetrating 
the protein molecules (Figure 4.9). The distance between the two bound sucrose 
octasulfates is 18 A, which suggests that four more sugar units of heparin could be 
accommodated between them. Including the two independently bound sucrose 
octasulfate, this results in a polysaccharide with eight sugar units, which is exactly the 
smallest size of heparin fragment required to bind two FGFs (19). Indeed, when an 
octasaccharide (without any sulfate groups) was built so as to have a helical heparin 
conformation and moved into the aFGF dimer to replace the two bound sucrose 
octasulfates, a reasonable fit was observed (Figure 4.1 0). Further, this hypothetical 
structure shows that Lys 35 from each of the aFGF monomers has its side chain 
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pointing towards the center of the octasaccharide and are likely to interact with 
heparin. 
The two monomers of this aFGF dimer that may bind heparin octasaccharide 
(Figure 4.1 0) are related by a non-crystallographic two fold axis. They are brought 
together mainly by interactions at the two ends of the molecular interface. Arg 116, 
which displays large side chain conformational change compared to the native aFGF 
structure, forms three hydrogen bonds with Asp 36 and Ser 38 of the neighboring 
aFGF molecule. In addition, salt bridges are formed between Arg 24 (molecule 1) and 
Asp 32 (molecule 2), and also possibly between Asn 114 (molecule 1), Lys 35 and 
Asp 37 (molecule 2) from two different aFGF monomers. Due to the approximate two 
fold symmetry relationship of the monomers, this interaction pattern is repeated at the 
other end of the dimer which thereby multiplies the intermolecular association 
affinity. 
In this dimer structure, a single sucrose octasulfate does not bind two aFGFs 
simultaneously to directly cause the dimerization. Instead, the conformational change 
at Arg 116 leads to six new hydrogen bonds and several salt bridges, which could be 
the major driving force for the dimerization. Based on this observation, as well as the 
fact that intermolecular interactions shown in this aFGF dimer have never been 
observed in the crystal forms without sucrose octasulfate (6, 9-11), it is probable that 
sucrose octasulfate can dimerize FGF in solution and that the dimerization interaction 
observed here could be physiologically relevant. This idea is supported by our recent 
observation that bFGF can be cross-linked in the presence of sucrose octasulfate (see 
Appendix). 
4.5. Possible mechanism of FGF binding to the receptor 
While the stoichiometry of FGF binding to its receptor is still unclear, it has been 
shown that cross-linking of FGF to its receptor results in a complex with a molecular 
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weight equivalent to one FGF plus one receptor, suggesting that each FGF possibly 
binds only one receptor (21, 22). This contradicts the possibility that two structurally 
distinct sites on a single FGF molecule may interact with two FGF receptor 
simultaneously (6, 9, 10, 11, 29). Recently, the binding mechanism of FGF to its 
receptor became even more complicated by the discovery that FGF binding to the 
receptor can occur only in the presence of heparin (23). Based upon this observation, 
as well as the identification of different putative receptor and heparin binding sites on 
FGF (Figure 4.8), it has been proposed that binding to heparin may result in 
significant conformational changes in FGF to induce the subsequent high affinity 
binding of FGF to its receptor (23). However the structure of aFGF in complex with 
the heparin analog sucrose octasulfate does not appear to support this hypothesis. 
Since no striking conformational change is observed in aFGF when it is bound to 
sucrose octasulfate, it is unlikely that large conformation changes in aFGF are 
prerequisite to receptor binding. 
Unlike dimeric peptide growth factors, such as PDGF and NGF, which can 
simultaneously bind two receptors to induce autophosphorylation of the receptor 
tyrosine kinase (24), FGF is a monomer and the attempts to trap FGF dimers in 
solution have so far been unsuccessful (T. Arakawa, personal communication). 
Recently, the observation of bFGF dimers in solution following the addition of 
heparin was reported (19). The transformation of FGF from a monomeric ligand to a 
dimeric ligand in the presence of heparin provides the possibility that FGF may 
interact with its receptor as a dimer, and hence cause the dimerization of two FGF 
receptors. While the FGF dimer structure formed in the presence of heparin is not 
known, the structure of aFGF and sucrose octasulfate complex may provide a 
reasonably analogous model (Figure 4.9 and 4.10). 
In this hypothetical model of the dimeric aFGF bound to a heparin octasaccharide, 
the two FGF monomers are related by a non-crystallographic two-fold symmetry axis. 
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Examples of other dimeric growth factors with a two-fold axis relating each monomer 
have been demonstrated in the crystal structures of NGF, TGF-13 and M-CSF (25-28), 
The interface of this aFGF dimer consists mainly of the region containing aFGF-(21-
41), a peptide which has been reported to be important for receptor binding (29). On 
the other hand, the second putative receptor binding site, aFGF-(97 -1 08), is located at 
the two ends of the dimer (Figure 4.11 ). Several lines of evidence suggest that the 
region of aFGF-(97 -1 08) is important for FGF binding to its receptor. For example, 
bFGF Thr 113 (corresponding to aFGF Ser 103), which is located in this region, can 
be phosphorylated by protein kinase A. The phosphorylated bFGF exhibits an 
enhanced binding affinity to the FGF receptor (30). Although, in general FGF is a 
highly homologous protein family with infrequent sequence insertions, the area 
between aFGF-(97 -108) is an exception. KGF and aFGF have four and two residue 
than bFGF respectively at this site while the two oncogenes int2 and FGF5 have an 
addition of 7 to 14 amino acids compared to bFGF. The high frequency of sequence 
insertions here suggests the functional importance of this site. Indeed while aFGF and 
KGF can interact with the same type of receptors, bFGF is shown to be unable to bind 
KGF receptors (31), which further supports the idea that receptor binding specificity 
is probably defined in this region. 
aFGF-(97 -1 08) has a similar solvent accessible surface area in the aFGF dimer as 
compared to its monomeric state. Each of these two identical sites located on the two 
faces of the dimer could bind one FGF receptor respectively, thereby dimerizing two 
FGF receptors (Figure 4.11). On the other hand, aFGF-(21-41) is fairly buried in the 
dimer interface and would be shielded from interaction with the FGF receptors. In 
fact, after dimerization, about 300 A2 is buried at the interface of the aFGF dimer. 
Based on this hypothetical dimer structure, aFGF-(21-41) may not contain the real 
receptor binding region. Instead, it may be required to form the intermolecular 
interface of the dimer which can then subsequently bind two FGF receptors (Figure 
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4.11). This model may explain why the peptides aFGF-(21-41) and aFGF-(97-108) 
are both able to inhibit FGF from interacting with its receptor. While the peptide 
aFGF-(21-41) may block FGF from binding to the receptor by disrupting formation of 
an FGF dimer which is required for FGF receptor binding, the peptide aFGF-(97 -1 08) 




FGF dimerization facilitated by sucrose octasulfate 
Since bFGF has been shown to cross-link as a dimer in the presence of heparin 
oligosaccharides ( 19), we attempted an analogous experiment in the presence of 
sucrose octasulfate. A similar cross-linking experiment procedure was followed, 
except that non-radiolabeled bFGF was used. FGF cross-linking experiments were 
carried out at room temperature in 0.5 ml microcentrifuge tubes. FGF and sucrose 
octasulfate were mixed to a final concentration of 1.6 mg/ml and 0.045 mg/ml, 
respectively, in a volume of 40 J.Ll. The mixture, also containing 140 mM NaCl, 20 
mM NaP04 (pH 7.4) and 0.025 mM P-mercaptoethanol, was incubated for half an 
hour. 1.5 J.Ll disuccinimidyl suberate, dissolved in DMSO to a concentration of 20 
mM, was then added to the mixture. After another 30 minutes, the reaction was 
quenched with 10 J.Ll ethanolamine-HCl (3 .85 M and pH 8.0). The final mixture was 
incubated for an additional 30 minutes and subjected to 12.5% SDS-PAGE. The 
polypeptide bands were visualized by Coomassie stain. 
The analog of [Ser70, Ser88] bFGF, which exhibits equal activity to the native 
bFGF, was used in the cross-linking experiment. Because a fraction of the protein 
sample has been dimerized through intermolecular disulfide bonds, P-
mercaptoethanol was added to the reaction solution in order to fully reduce the 
disulfide bridges. In the absence of sucrose octasulfate, no significant bFGF dimers 
was detected after addition of the cross-linking reagent DSS (Figure 4.12, lane 4). 
However, bFGF dimerization was observed to occur when sucrose octasulfate was 
added (Figure 4.12, lane 3). Sucrose octasulfate has been demonstrated to be 
functionally similar to heparin before. This cross-linking experiment further 
demonstrates the functional similarity of sucrose octasulfate to heparin. 
A similar experimental procedure was also applied to aFGF, except that the 
concentration of aFGF used was about 1.3 mg/ml. No cross-linked aFGF was 
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observed (Figure 4.12, lane 1 and 2), even after the sucrose octasulfate concentration 
was much increased (data not shown here). One possibility for aFGF not to cross-link 
as a dimer is that the cross-linking reagent is more efficient for basic proteins and 
aFGF has a much lower isoelectric point. Therefore, other cross-linking reagents are 
being tested. 
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Table 4.1. An Illustration of Intensity Distribution of the Data 
H K L Foos Sigma 
0 2 4 82.100 0.080 
0 2 5 0.080 5.840 
0 2 6 34.970 0.130 
0 2 42 15.410 0.380 
0 2 43 0.000 999.0 
0 2 44 3.580 1.430 
0 2 45 6.230 0.820 
0 2 46 27.110 0.400 
TABLE 4.2. Heavy Atom Refmement Statistics 
Derivative Reso- Concen- measured comp- Rsym Refined fHIE 
lution tration reflection lete (%) Sites 
Native 2.1 A 31,326 95% 11.8 
EMTS 3.4A 2.5 mM 16,070 92% 12.2 8 1.26 
K2PtCl4 2.3 A 3.0mM 45,881 91% 9.28 14 0.84 
1 
fH IE= [L/~ I ~)F deriv,obs- F deriv,ca~c>2l2 
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Figure 4.1. lllustration of the 8-fold averaged electron density map in the region near 
His 93. 
Figure 4.2. lcr level electron density around a sucrose octasulfate molecule [(2F0 -
Fc) <Xcalc)], calculated at 2.7 A resolution. 
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Figure 4.3. Binding of sucrose octasulfate to aFGF. The j3 strand that is involved in 













































































































































































































































































































































































































































































Figure 4.6. Superposition of the eight sucrose octasulfate molecules that are related 
by noncrystallographic symmetry. Figure 4.6 (2) to (8) reveal the sucrose octasulfate 
structures of #2 to #8 (thin line) superimposed to sucrose octasulfate #1, based on the 
corresponding aFGF molecules. Sucrose octasulfate #1 is shown in the thick line. 
Figure 4.6 (1): Superposition of the sucrose octasulfate bound to aFGF determined by 
us (#1, shown with thick line) and the free sucrose octasulfate determined by small 






Figure 4.7. Sequence alignment of acidic and basic FGF in the sucrose octasulfate 
binding region. 
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Figure 4.8. The structure of aFGF bound to sucrose octasulfate. The two putative 
receptor binding sites, which are near residues 38 and 104 respectively, are shown 



















































































































































































































































































































































































Figure 4.12. Dimerization of FGF. Lane 1, cross-linking of aFGF in the absence of 
sucrose octasulfate; Lane 2, cross-linking of aFGF in the presence of sucrose 
octasulfate; Lane 3, cross-linking of bFGF in the absence of sucrose octasulfate; Lane 
4, cross-linking of bFGF in the presence of sucrose octasulfate. 
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Chapter 5 




Since FGFs can induce mitogenic, chemotactic and angiogenic activity in a 
variety of cells of epithelial, mesenchymal and neural origins ( 1 ), FGF is a very 
attractively therapeutic target. With the ability to promote tissue repair (2), FGF has 
been considered as a potential drug for wound healing. On the other hand, some 
members of the family are highly expressed in many malignantly transformed cells 
(3). Therefore, inhibition of FGF activity in these cells may be useful. To use FGF as 
a tissue growth promoting drug, high therapeutic efficiency is usually connected with 
the high stability of the protein. One potential way of enhancing FGF stability is to 
introduce specific mutations into FGF. To investigate how mutations can change FGF 
stability, two mutant structures have been determined and will be discussed in this 
chapter. Furthermore, to be used as a routine therapy, high yield and efficiency of 
protein purification is required to prepare large quantities ofFGF. Copper and heparin 
biaffinity columns have been demonstrated to have increased FGF binding affinity 
(4). The structure of FGF and copper complex has been studied. Finally, the structure 
of an FGF-inhibitor analog complex is analyzed to provide a structural basis for 
rational design of drugs to either enhance or inhibit FGF activity. 
5.2. The mutant Gly93His aFGF structure 
While the mutant Ala47Cys aFGF exhibits comparable activity to the native 
aFGF, the substitution of glycine for histidine 93 in aFGF has been shown to increase 
aFGF stability (5). The thermal denaturation temperature of Ala47Cys/Gly93His 
aFGF is about 10 oc higher than Ala 47 aFGF. This is consistent with the observation 
that while [Ala47] aFGF rapidly loses mitogenic activity in the absence of heparin 
(with a half-life of approximately 13 hours (5)), [Ala47, Gly93] aFGF exhibits no loss 
of activity over 250 hours in the same conditions. In addition, [Ala47, Gly93] aFGF 
appears to have slightly higher activity because it can produce the same mitogenic 
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effect as the [Ala47] aFGF analog or the native aFGF but at lower concentrations. 
Furthermore, because [Ala47, Gly93] aFGF can be eluted from a heparin column at an 
identical concentration of NaCl required for [Ala47] aFGF, the stability of [Ala47, 
Gly93] aFGF does not seem to be due to its increased binding affinity for heparin. In 
order to provide a structural basis for comparing the stability of the [Ala47] and 
[Ala47, Gly93] aFGF analogs, their crystal structures were determined. 
In the [Ala47, Gly93] aFGF structure (6), it is shown that residues 90 to 94 have a 
sequence of Glu Glu Asn Gly Tyr and form a 3:5 ~-hairpin as defined by Sibanda, et 
a/. (7). A 3:5 ~-hairpin consists of two terminal amino acids from two adjacent ~ 
strands with three intermediate residues forming a tight ~ turn. This hairpin structure 
is a combination of a classic type I ~ turn and a G 1 ~-bulge (8, 9) which possesses a 
conformation of ~<lR<lR<lL~. where <lL stands for left-handed alpha helix and <lR for 
right-handed alpha helix. Since the main chain torsion angles for the fourth residue of 
the loop are in the left hand alpha helical region of the Ramachandran plot, glycine is 
the most easily accommodated amino acid at this position. The most common amino 
acids observed to replace glycine in the 3:5 ~-hairpin are asparagine and aspartic acid 
(10), although asparagine is seen more frequently (9). Indeed, basic FGF, which has a 
similar main chain conformation as aFGF in this region (Figure 5.1), has an 
asparagine at the fourth position of the hairpin. 
Although the structure of [Ala47, Gly93] aFGF suggests that glycine should be the 
most energy-favored amino acid at position 93, it could be interesting to determine 
the [Ala47] aFGF structure and compare the structures of the naturally occurring 
[His93] aFGF with the [Gly93] aFGF analog. Thin plates of hexagonal crystals of 
[Ala47] aFGF were obtained by using the similar crystallization conditions for [Ala47, 
Gly93] aFGF (6), but they only diffracted to about 4 A resolution. Conditions for 
better quality crystals were then screened with a factorial method (11) in the presence 
of sucrose octasulfate which can generally stabilize FGF (2). The details of 
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crystallization and structure determination are described in Chapter 4. 
The crystal structure of the [Ala47] aFGF-sucrose octasulfate complex reveals the 
well defined side chain position of His 93 (Figure 4.1 ). Further, the side chain of His 
93 is highly exposed to solvent and is not in contact with the rest of the aFGF 
molecule. The overall geometry of the 3:5 hairpin around position 93 in [Ala47] aFGF 
is quite similar to that in [Ala4 7, Gly93] aFGF (Figure 5.2). In addition, the main 
chain torsion angles of histidine 93 are observed to be maintained in a left-handed 
alpha helix conformation. Therefore, as demonstrated by this structure, in addition to 
asparagine and aspartate, histidine can also be accommodated at the 4th position of a 
typical 3:5 hairpin and adopt a left-handed alpha helix conformation. However, 
relative to glycine, a histidine in the fourth position of a 3:5 hairpin is less favorable 
and hence leads to decreased stability of aFGF. 
5.3. The mutant Asp40Arg bFGF structure 
Another mutant FGF that was studied was the Asp40Arg bFGF analog. Arginine 
40 is one of the positively charged residues located in the region of bFGF-(31-51) 
which has been reported to be important in receptor binding and probably also in 
heparin binding (9). Surprisingly, mutation of arginine 40 to an aspartic acid resulted 
in an active bFGF, although it appears to be less stable at low ionic strength (10). To 
further investigate the property of the mutant, the structural determination of 
Asp40Arg bFGF has been carried out. 
Crystallization trials with the low ionic precipitant solution PEG8K, from which 
the [Arg40]bFGF crystals have been obtained (4), failed to produce any [Asp40] bFGF 
crystals. Instead, screening with factorial conditions (7) yielded crystals of 0.5 x 0.5 x 
0.5 mm3 in size that diffracted to about 1. 7 A resolution. Each droplet contains equal 
volumes of the [Asp40] bFGF sample at a concentration of 10 mg/ml and the reservoir 
solution of 2.0 M (NJ-4)2S04 and 0.2 M Na Citrate at pH 5.6. These crystals belong 
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to the space group P2t2t2I and have cell dimensions of 31.8 A, 42.1 A and 86.1 A. 
At about the same time as the [Asp40] bFGF crystals were obtained, the same crystal 
form of the native bFGF crystals was reported to be crystallized in 60% saturated 
ammonium sulfate and 0.2 M sodium succinate (pH 5.3) (12). 
The mutant structure of Asp40Arg bFGF was determined by a combination of 
molecular replacement and single isomorphous replacement (SIR) method. Using the 
determined bFGF structure (4), a clear molecular replacement solution with an R-
factor of 38.0% was obtained by using the Crowther fast rotation function (13) and 
the brute-force translation search (14) when diffraction data within 4 to 8 A resolution 
were used. In addition, rigid body refinement of the molecular replacement model 
with TNT (15) lowered the R-factor down to 36.7% using the same reflections. The 
difference Fourier (F0 - Fe) map calculated with the model phases, however, 
displayed no density for the aspartic acid side chain. To improve the model phases, 
several cycles of positional refinement with TNT to 3 A resolution was carried out. A 
model with an R-factor of 26.1% and r.m.s. deviations from the ideal bond distances 
and bond angles of0.023 A and 3.6°, respectively, was obtained. The difference map 
phased with this model still did not reveal side chain density for Asp 40. 
An ETMS derivative data set was then collected in order to further improve the 
phases. The heavy atom binding site, located from a difference Patterson map (Figure 
5.3), was consistent with that located from a difference Fourier map using the 
molecular replacement phases. In addition, the mercury binding site was near the 
solvent exposed cysteine 93 residue, which further supported the correctness of the 
molecular replacement. The single isomorphous replacement phases were 
subsequently calculated by refining the Hg binding site against the difference 
Patterson with HEAVY (16) (Table 5.1). After the SIR phases were combined with 
the molecular replacement phases, the density of the C13 atom of Asp 40 was found in 
the electron density map calculated with the combined phases. Building in an alanine 
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at position 40 followed by several cycles of refinement, manual adjustment of the 
model and phase combination finally made it possible to model in an aspartic acid. 
Refinement of the [Asp40] bFGF model to 1.7 A proceeded to an R factor of 18.4%, 
with the root-mean-square deviations from the ideal bond distances and angles of 
0.016 A and 2.7°, respectively (Figure 5.4). 
The overall structure of [Asp40] bFGF is very similar to the model of [Arg40] 
bFGF which was used during the molecular replacement solution. The root-mean-
square difference of the 124 corresponding a-carbons is only 0.61 A. Surprisingly, 
the change of arginine to aspartic acid at residue 40 does not cause any large 
structural disturbance in this region (Figure 5.5). The positional deviation between the 
Cas of amino acid 40 in the two structures is only 0.14 A. Yet, in spite of the similar 
backbone structures around residue 40, the side chains of Arg 40 and Asp 40 exhibit 
quite different conformations (Figure 5.6). In the crystal structure, Arg 40 is localized 
at the beginning of 13-strand 3 and its side chain is mainly stabilized by forming two 
hydrogen bonds with an adjacent amino acid, Asp 38. In addition, Arg 40 is involved 
in a lattice contact and is further stabilized by interacting with two asparagines of a 
neighboring molecule. It is hence expected that the substitution of the arginine to 
aspartic acid would lead to the disruption of all the interactions that Arg 40 is 
involved in, and would result in an altered structure. Indeed, the mutant Asp 40 
structure shows that the Asp 40 side chain does not interact with Asp 38. Nor is it in 
contact with the neighboring molecule. Nevertheless, the mutant structure reveals that 
Asp 40 bFGF appears to remain a stable structure. Instead of forming the interactions 
observed in [Arg40] bFGF, Asp 40 is stabilized by interacting with the neighboring 
amino acid histidine 36. His 36 is observed to display a large conformational change 
in the D40 mutant structure (Figure 5.6). By moving closer to Asp 40, His 36 is able 
to be hydrogen bonded to Asp 40. In addition, a new hydrogen bond is formed 
between Asp 42 and the repositioned His 36. Therefore, according to this structure, it 
Ill 
seems that [Asp40] and [Arg40] bFGF may have comparable stabilities. Indeed, this is 
confmned by other biochemical studies after the structure was solved (T. Arakawa, 
personal communication). 
While the [Asp40] bFGF Ca backbone is shown to remain a similar configuration 
to that of [Arg40] bFGF, considerably larger conformational differences are observed 
in the regions far away from amino acid 40. For instance, the Ca positional 
differences of residues 101, 102 and 103 in the two structures are as large as 2.6 A, 
3.3 A and 2.2 A, respectively (Figure 5.7). The structural analysis shows that the 
conformational divergence is mainly caused by a lattice contact. Amino acids 101, 
102 and 103 are three continuous negatively charged residues localized in the loop 
between the 13 strands 8 and 9, which is extensively involved in the interactions with 
the neighboring molecules. In the [Asp40] bFGF crystal form, the main chain 
carbonyl group and the side chain of Asn 102 form hydrogen bonds with Arg 45 and 
Glu 46 of a neighboring bFGF. In addition, the same Arg 45 also interacts with Asn 
103. In the [Arg40] bFGF crystal form, however, Asn 102 is not involved in lattice 
contacts, while Asn 103 is hydrogen bonded to Arg 40 from an adjacent bFGF. 
Therefore, the dramatic structural difference demonstrated here is probably not an 
intrinsic characteristic of this loop. Instead, it is mainly caused by a lattice contact in 
the crystal. This idea is further supported by the structural similarity of the Asn 102 
region in this [Arg40] bFGF structure to another [Arg40] bFGF structure, which was 
independently determined in a new crystal form (17). Furthermore, interactions 
between neighboring molecules are also responsible for the second largest structural 
variance revealed in these two structures (Figure 5.5). Located in a 13 turn, Arg 61 
forms a hydrogen bond to Glu 79 of an adjacent bFGF in the 040 crystal form, 
whereas the same residue in the [Arg40] crystal (6) is not involved in any lattice 
contact. 
Because of the lattice contact effect, it is often asked how reliable protein crystal 
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structures are. A further related question is to ask whether water molecules located in 
crystal structures are physiologically relevant. The two high resolution bFGF 
structures determined by us as well as other independently determined bFGF 
structures provide an excellent example for this kind of analysis. 
At least three different bFGF crystal forms that diffract beyond 2.0 A have been 
reported (6, 12,17) using both high and low ionic strength precipitant solutions. This 
includes two different triclinic P1 forms, crystallized in PEG or ammonium sulfate (6, 
17), and an orthorhombic crystal form obtained with ammonium sulfate (12). 
Interestingly, the two bFGF structures determined in P1 space group 
(1BAS_BFGF.PDB and 3FGF.PDB) have more similar conformations despite very 
different ionic strength precipitant solutions were used. The root-mean-square 
difference of the 124 corresponding a-carbons is only 0.25 A. This is almost within 
experimental error because the two independently determined bFGF structures by us 
and others using the same crystal form and similar crystallization conditions also 
reveal an r.m.s. difference of 0.25 A for the Ca atoms. On the other hand, the bFGF 
structures determined in the orthorhombic form show more structural divergence 
compared to the ones determined in the triclinic forms, with an r .m.s. difference of 
approximately 0.6- 0.7 A. This suggests that different lattice contacts associated with 
changes in space group could cause more conformational differences than different 
crystallization conditions. 
In the three different bFGF crystal forms, forty (6), seventy (17) and eighty (D40 
structure) water molecules were located. While nineteen water molecules are found at 
similar positions in the two Pl bFGF crystal forms, fifteen of these are common in all 
three crystal forms. In addition, eleven common water molecules are located on the 
protein surface and most of them are bound to main chain amide and carbonyl groups. 
Therefore, it may be concluded that although some of the solvent molecules binding 
to proteins appear to have ordered structures due to the crystal packing effect, others 
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are physiologically relevant and could play important roles in mediating protein 
function. 
5.4. Inhibition of FGF activity by suramin 
Although it has been shown that polysulfated glucosaminoglycans are required for 
FGF binding to its high affinity receptor (18-20), other polysulfated compounds 
inhibit interaction between FGF and its receptor (21, 22). One of the polyanionic FGF 
inhibitors which has therapeutic potential against tumor cell growth is suramin (23). 
Suramin is a symmetrical polysulfonated naphthylurea which has been 
extensively used for the treatment of tryposnosomiasis and onchocerciasis (24) 
(Figure 5.8). In addition, suramin has been known to possess anti-proliferative 
activities possibly by inhibiting the binding of various growth factors with their 
receptors (25, 26). Experimental evidence for direct interaction of suramin with 
growth factors has recently been reported (27) by the observations that 1) the 
fluorescence of suramin is significantly enhanced in the presence of aFGF; 2) heparin 
effectively competes with suramin binding to aFGF; 3) the presence of suramin 
stabilizes aFGF from thermal denaturation and also prevents formation of aFGF 
intermolecular disulfide bonds. In addition, based on the observation that the 
molecular weight of aFGF is six times higher after suramin is added in a molar ratio 
of 2: 1, one of the possible inhibitory mechanisms of suramin on FGF activity may be 
that suramin can cause FGF microaggregation. 
To further understand the detailed interactions between suramin and FGF, as well 
as to obtain a structural basis for rational drug designs of better anti-tumor agents, 
crystallographic studies of the FGF and suramin complex were attempted. The 
importance of FGF in carcinogenesis has previously been suggested by the observed 
high concentration of FGF in various tumor cell lines. Recently, direct cellular 
malignant transformation by FGF oncogenes or by bFGF fused with a signal peptide 
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sequence has been demonstrated (21). Furthermore, it is shown that the autocrine 
transformation process induced by the chimeric bFGF can be blocked with the 
addition of suramin (21). Therefore, the use of suramin or suramin analogs has been 
suggested to be a potentially powerful therapy against autonomous cell growth and 
tumorgenesis. 
Attempts to cocrystallize either aFGF or bFGF with suramin have not been 
successful, mainly due to the problem of FGF precipitation in the presence of 
suramin. However, when 1,3,6-naphthalene trisulfonate, which is a close analog of 
half of a suramin molecule in structure, was diffused into an aFGF crystal (6), it was 
found to bind an aFGF dimer with high occupancy. The bound 1 ,3,6-naphthalene 
trisulfonate was located in the difference Fourier map (F0 - Fe), calculated with the 
phases from the aFGF structure (6). After manually fitting of 1,3,6-naphthalene 
trisulfonate into the difference density, the complex structure was refined to 3 A using 
the XPLOR package (28) The refinement has progressed to a current R-factor of 
16.2% with 0.013 A for the r.m.s. bond length deviation and 2.3° for the r.m.s. bond 
angle deviation. 
The refined structure of aFGF and 1,3,6-naphthalene trisulfonate complex 
demonstrates that one 1,3,6-naphthalene trisulfonate binds two aFGF molecules 
simultaneously around the regions of Arg 24 on one aFGF and Lys 128 on the other 
(Figure 5.10). Two lysines around the sucrose octasulfate binding region, Lys 113 and 
Lys 128, form hydrogen bonds to two sulfate groups of 1,3,6-naphthalene 
trisulfonate. 1,3,6-naphthalene trisulfonate also binds another neighboring molecule 
through hydrogen bonds with the side chain of Arg 24 and the main chain amide of 
Asp 28. In addition, the binding is strengthened by hydrophobic interactions. The 
aromatic ring of the naphthalene is sandwiched between Leu 26 from one aFGF and 
carbon atoms of the Lys 113 side chain from the other (Figure 5.11). 
Since the growth factors inhibited by suramin are primarily heparin binding 
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proteins (29), direct interaction of the proteins with suramine in a similar manner as 
heparin has been speculated. This similarity is further supported by the recent report 
that heparin competes with suramin to bind FGF and vice versa (27). The structure of 
the aFGF-1,3,6-naphthalene trisulfonate complex shows that the proposed heparin 
binding site on aFGF is likely to be involved in interacting with suramin. Although 
1,3,6-naphthalene trisulfonate binds two aFGF monomers, the major binding site is 
within the region near Lys 118, which has been suggested to be the heparin binding 
site according to the crystal structure analysis as well as other biochemical results (6, 
30). Among the residues of Asn 18, Lys 112, Lys 113, Asn 114, Arg 116, Lys 118, 
Arg 122, Gln 127 and Lys 128 that are involved in binding to sucrose octasulfate, Asn 
18, Lys 112 and Lys 113 of one aFGF form four hydrogen bonds with the bound 
1,3,6-naphthalene trisulfonate (Figure 5.11), implying that the inhibitory influence of 
suramin upon the activity of aFGF may be at least partially due to the occupation of 
the heparin binding site on aFGF by suramin. Further, in addition to this binding site, 
the structure of the complex reveals that the region between Arg 24 and Asp 28 are 
also involved in 1,3,6-naphthalene trisulfonate binding. The importance of the aFGF-
(21-41) region in receptor binding has been reported before (30). Furthermore, the 
same region has been further suggested to possibly be located at the interface of the 
aFGF dimer that binds the FGF receptors (Chapter 4). Therefore, it is also likely that 
suramin disrupts the interactions of FGF with its receptor by occupying the sites 
which are important for FGF binding to the receptor. Finally, since suramin is 
reported to induce FGF microaggregation (27), the structure of one 1,3,6-naphthalene 
trisulfonate binding to two aFGF molecules provides a possible model of how one 
suramin may bind several FGF molecules simultaneously. 
5.5. The FGF Cu binding site 
Copper has been known to modulate the neovascular response from angiogenic 
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stimuli as FGF. While some studies indicate that FGF binding to heparin requires 
copper (31-36), others report that FGF could interact with heparin even in the absence 
of copper (37). FGFs were shown to potentially possess different heparin and copper 
binding sites (37). Shing further showed that although a copper-Sepharose column 
alone is not sufficient to bind either aFGF or bFGF, the biaffinity chromatography of 
copper-heparin is more efficient than heparin affinity columns to resolve aFGF from 
bFGF as well as the multiple forms of aFGF or bFGF (37). 
To confirm the direct interactions between FGF and copper, the difference Fourier 
method has been employed to locate the possible copper binding site on FGF. 
Unfortunately, soaking of bFGF crystals (6) in the synthetic mother liquor of 30% 
PEG8K and 0.1 M Hepes buffer (pH 7.5) in the presence of high concentration of 
CuCh did not successfully incorporate copper into the crystals. Based on speculation 
that the CuCl2 may form Cu(OH)2 precipitant at the crystallization pH, the bFGF 
crystals (6) were soaked for about 10 hours in a solution of 30% PEG8K and 5 mM 
CuCh without the buffer solution. The collected 3 A area detector data of the soaked 
bFGF crystal revealed a clear difference Fourier peak between histidines 36 and 51 
(Figure 5.12). It was further shown in the structure that few local conformational 
changes occur in this region. Both histidines 31 and 51 bind Cu2+ through the N 0 
atoms and the angle between N036, Cu and N051 is about 1200. Furthermore, the 
copper binding site on bFGF is remotely located from the heparin binding site, with a 
distance of 15 A between His 36 and Lys 118, the residue shown to intimately 
interact with sucrose octasulfate (Figure 5.13). 
Soaking of aFGF crystals (6) with CuCh failed to produce crystals with 
incorporated copper. This may be due to the chelation of copper by Na Citrate which 
is the buffer used in crystallization (6). Although the structure of aFGF and copper 
complex is not yet available, sequence alignment analysis shows that the copper 
binding site revealed in bFGF is not conserved in aFGF. Corresponding to bFGF His 
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36 is Leu 26 in aFGF. Nevertheless, despite the sequence divergence, aFGF has been 
reported to have a stronger binding affinity for copper than bFGF (37). Therefore, a 
different binding site on aFGF may be involved in binding to copper. Further 
structural analysis of aFGF shows that two histidines in aFGF, His 106 and His 124, 
are quite close to each other in the three dimensional structure. In addition, one water 
molecule is found to be bound between the two histidines in the refined aFGF 
structure. Furthermore, K2PtCl4, which has been used as the heavy atom derivative 
for the aFGF structure determination, was found to bind aFGF histidines 106 and 124 
simultaneously in two different aFGF crystal forms (6) (Chapter 4). Hence it is very 
likely that copper binds aFGF through these two histidines. Also, as in bFGF, this 
putative copper binding site is separate from the heparin binding site (Figure 5.14). 
The distance between His 106 and Lys 112, which is involved in sucrose octasulfate 
binding, is more than 20 A. This is in agreement with the biochemical studies that 
copper and heparin binding sites appear to be separate (37). 
The distinct binding sites of copper and heparin on FGF explain why a copper and 
heparin biaffinity column is more efficient for FGF purification than a heparin 
column alone. These sites could be used to design engineered metal-binding FGF to 
further increase the protein purification efficiency. For example, a copper binding site 
similar to bFGF may be generated by changing aFGF Leu 26 to histidine so that 
aFGF may have two different copper binding sites around Leu 26 and His 106. 
Furthermore, either the present copper binding sites or engineered sites on FGF could 
be used to bind other metals. One of the possible therapeutic applications for FGF-
metal complexes involves using radiolabled metals such as 57Co for the detection or 
the treatment of tumor cells. 
118 
Table 5.1. EMTS SIR Phases Statistics 
Resolution 
FOM 
P. P. (centric) 
P. P. (acentric) 
6.75 4.42 3.50 2.99 
0.55 0.47 0.44 0.38 
2.25 1.78 1.74 1.52 
3.85 2.86 2.55 2.27 
FOM: Figure of Merit 
P . P.: Phasing Power 
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2.65 2.40 2.21 
0.36 0.33 0.31 
1.48 1.22 1.05 





Figure 5.1. The superimposed 3:5 P-hairpin structures of [Ala47, Gly93] aFGF (thick 
line) and bFGF (thin line) near aFGF residue Gly 93. The hydrogen bonds between 
the strands 8 and 9 are shown with the dashed lines. 
Figure 5.2. Structural superposition of [Gly93] aFGF (thick line) and [His93] aFGF 
(thin line). 
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Figure 5.6. The region near residue 40 in the superimposed [Asp40] (thick line) and 
[Arg40] (thin line) bFGF crystal structures. 
Figure 5.7. Conformational difference near Asn 102 in the two crystal forms of 




































































































Figure 5.10. The binding of one 1 ,3,6-naphthalene trisulfonate molecule to an aFGF 
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Figure 5.11. Interactions between two aFGF molecules and the bound 1,3,6-





































































Figure 5.13. Copper (shown with van der Waals surface) and heparin binding sites 
on bFGF. The side chains of bFGF-(120-130), which are likely to interact with 
hepairn, are shown with thin lines. 
Figure 5.14. Possible copper (shown with van der Waals surface) and heparin 
binding sites on aFGF. The aFGF backbone has a similar orientation to bFGF shown 
In Figure 5.13. The side chains of aFGF-(112-122), which are likely to interact with 
heparin, are shown with thin lines. 
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